Streptavidin
OrganismNot specified
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count | Chain A； UniProt 40–158 Chain B； UniProt 40–158 Chain C； UniProt 40–158 Chain D； UniProt 40–158 | Not recorded | BTN BIOTIN × 4 | ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：Cryogen ETHANE | Resolution 3.20 Å |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 6J6J | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1DF8 S45A MUTANT OF STREPTAVIDIN IN COMPLEX WITH BIOTIN Deposited 1999-11-18 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
3–129（127 aa）
Fragment：CORE, RESIDUES 13-139
Chain B
3–129（127 aa）
Fragment：CORE, RESIDUES 13-139
|
Mutation：S45A Mutation：S45A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；294 K；40% SATURATED AMMONIUM SULFATE, 0.1 M SODIUM ACETATE, pH 4.5, temperature 294.K
|
Resolution 1.51 Å R-free 0.225 |
| 1DF8 S45A MUTANT OF STREPTAVIDIN IN COMPLEX WITH BIOTIN Deposited 1999-11-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
3–129（127 aa）
Fragment：CORE, RESIDUES 13-139
Chain B
3–129（127 aa）
Fragment：CORE, RESIDUES 13-139
|
Mutation：S45A Mutation：S45A | BTN BIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；294 K；40% SATURATED AMMONIUM SULFATE, 0.1 M SODIUM ACETATE, pH 4.5, temperature 294.K
|
Resolution 1.51 Å R-free 0.225 |
| 1HQQ MINIPROTEIN MP-2 (M9A) COMPLEX WITH STREPTAVIDIN Deposited 2000-12-19 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–129（129 aa）
Chain B
1–129（129 aa）
Chain C
1–129（129 aa）
Chain D
1–129（129 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；298 K；100 mM potassium acetate, ammonium sulfate, pH 4.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å R-free 0.249 |
| 1HXL MINIPROTEIN MP-2 (V10A) COMPLEX WITH STREPTAVIDIN Deposited 2001-01-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–129（129 aa）
Chain B
1–129（129 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.8；298 K；100 MM POTASSIUM ACETATE, AMMONIUM SULFATE, pH 4.80, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å R-free 0.236 |
| 1HXZ MINIPROTEIN MP-2 COMPLEX WITH STREPTAVIDIN Deposited 2001-01-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–129（129 aa）
Chain B
1–129（129 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；298 K；100mM potassium acetate, 32% AMMONIUM SULFATE , pH 4.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å R-free 0.230 |
| 1HY2 MINIPROTEIN MP-1 COMPLEX WITH STREPTAVIDIN Deposited 2001-01-17 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–129（129 aa）
Chain B
1–129（129 aa）
Chain C
1–129（129 aa）
Chain D
1–129（129 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；298 K；100mM potassium acetate, ammonium sulfate, pH 4.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.258 |
| 1I9H CORE STREPTAVIDIN-BNA COMPLEX Deposited 2001-03-20 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–163（139 aa）
Fragment：RESIDUES 25-163
Chain B
25–163（139 aa）
Fragment：RESIDUES 25-163
|
Not recorded | BNI 5-(2-OXO-HEXAHYDRO-THIENO[3,4-D]IMIDAZOL-6-YL)-PENTANOIC ACID (4-NITRO-PHENYL)-AMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；10% isopropanol, 0.1M NaCitrate, 0.05M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.250 |
| 1KFF An engineered streptavidin with improved affinity for the strep-tag II peptide: apo-SAM1 Deposited 2001-11-20 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
Chain C
38–163（126 aa）
Chain D
38–163（126 aa）
|
Mutation：E44V,S45T,V47R Mutation：E44V,S45T,V47R Mutation：E44V,S45T,V47R Mutation：E44V,S45T,V47R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；100 mM Na2HPO4, 1.2-M (NH4)2SO4, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.229 |
| 1KL3 an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm1-StrepII Deposited 2001-12-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
Chain C
38–163（126 aa）
Chain D
38–163（126 aa）
|
Mutation：E44V,S45T,V47R Mutation：E44V,S45T,V47R Mutation：E44V,S45T,V47R Mutation：E44V,S45T,V47R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；100 mM Na2HPO4, 1.3-M (NH4)2SO4, pH 6.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.217 |
| 1KL4 AN ENGINEERED STREPTAVIDIN WITH IMPROVED AFFINITY FOR THE STREP-TAG II PEPTIDE : apo-SAM2 Deposited 2001-12-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
Chain C
38–163（126 aa）
Chain D
38–163（126 aa）
|
Mutation：E44I,S45G,V47R Mutation：E44I,S45G,V47R Mutation：E44I,S45G,V47R Mutation：E44I,S45G,V47R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；50 mM Na3PO4, 50 mM Na3-citrate, 30% PEG 600, pH 6.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.228 |
| 1KL5 an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm2-StrepII Deposited 2001-12-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
Chain C
38–163（126 aa）
Chain D
38–163（126 aa）
|
Mutation：E44I,S45G,V47R Mutation：E44I,S45G,V47R Mutation：E44I,S45G,V47R Mutation：E44I,S45G,V47R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM Na2HPO4, 1.2-M (NH4)2SO4, pH 7.50, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.221 |
| 1LCV streptavidin-norbiotin complex Deposited 2002-04-07 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
|
Not recorded | SNR NORBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；293 K；1.2 M ammonium sulfate, 0.1M sodium acetate, pH 4.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.233 |
| 1LCV streptavidin-norbiotin complex Deposited 2002-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
|
Not recorded | SNR NORBIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；293 K；1.2 M ammonium sulfate, 0.1M sodium acetate, pH 4.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.233 |
| 1LCW streptavidin-homobiotin complex Deposited 2002-04-07 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
|
Not recorded | SHM HOMOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；293 K；ammonium sulfate, sodium acetate, pH 4.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.233 |
| 1LCZ streptavidin-BCAP complex Deposited 2002-04-08 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–159（135 aa）
Chain B
25–159（135 aa）
|
Not recorded | BH7 E-AMINO BIOTINYL CAPROIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；293 K；1.2M ammonium sulfate, 0.1M sodium acetate, pH 4.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.237 |
| 1LCZ streptavidin-BCAP complex Deposited 2002-04-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
25–159（135 aa）
Chain B
25–159（135 aa）
|
Not recorded | BH7 E-AMINO BIOTINYL CAPROIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；293 K；1.2M ammonium sulfate, 0.1M sodium acetate, pH 4.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.237 |
| 1MEP Crystal Structure of Streptavidin Double Mutant S45A/D128A with Biotin: Cooperative Hydrogen-Bond Interactions in the Streptavidin-Biotin System. Deposited 2002-08-08 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：Core streptavidin (residues 13-139)
Chain B
37–163（127 aa）
Fragment：Core streptavidin (residues 13-139)
Chain C
37–163（127 aa）
Fragment：Core streptavidin (residues 13-139)
Chain D
37–163（127 aa）
Fragment：Core streptavidin (residues 13-139)
|
Mutation：S45A, D128A Mutation：S45A, D128A Mutation：S45A, D128A Mutation：S45A, D128A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；sodium citrate, cacodylate, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 1.65 Å R-free 0.295 |
| 1MK5 Wildtype Core-Streptavidin with Biotin at 1.4A. Deposited 2002-08-28 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：Core Streptavidin (residues 13-139)
Chain B
37–163（127 aa）
Fragment：Core Streptavidin (residues 13-139)
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；ammonium sulphate, sodium acetate, sodium chloride, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.40 Å R-free 0.189 |
| 1MM9 Streptavidin Mutant with Insertion of Fibronectin Hexapeptide, including RGD Deposited 2002-09-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：Core Streptavidin (residues 13-139)
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.66 Å R-free 0.195 |
| 1MM9 Streptavidin Mutant with Insertion of Fibronectin Hexapeptide, including RGD Deposited 2002-09-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：Core Streptavidin (residues 13-139)
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.66 Å R-free 0.195 |
| 1MM9 Streptavidin Mutant with Insertion of Fibronectin Hexapeptide, including RGD Deposited 2002-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
37–163（127 aa）
Fragment：Core Streptavidin (residues 13-139)
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.66 Å R-free 0.195 |
| 1MOY Streptavidin Mutant with Osteopontin Hexapeptide Insertion Including RGD Deposited 2002-09-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.55 Å R-free 0.185 |
| 1MOY Streptavidin Mutant with Osteopontin Hexapeptide Insertion Including RGD Deposited 2002-09-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.55 Å R-free 0.185 |
| 1MOY Streptavidin Mutant with Osteopontin Hexapeptide Insertion Including RGD Deposited 2002-09-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.55 Å R-free 0.185 |
| 1N43 Streptavidin Mutant N23A with biotin at 1.89A Deposited 2002-10-30 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：N23A Mutation：N23A Mutation：N23A Mutation：N23A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.89 Å R-free 0.301 |
| 1N4J STREPTAVIDIN MUTANT N23A AT 2.18A Deposited 2002-10-31 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：N23A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；293 K；PEG4000, phosphate buffer, pH 6.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.18 Å R-free 0.253 |
| 1N7Y STREPTAVIDIN MUTANT N23E AT 1.96A Deposited 2002-11-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：N23E Mutation：N23E Mutation：N23E Mutation：N23E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.96 Å R-free 0.284 |
| 1N9M Streptavidin Mutant S27A with Biotin at 1.6A Resolution Deposited 2002-11-25 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：S27A Mutation：S27A Mutation：S27A Mutation：S27A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.207 |
| 1N9Y Streptavidin Mutant S27A at 1.5A Resolution Deposited 2002-11-26 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：S27A Mutation：S27A Mutation：S27A Mutation：S27A | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.53 Å R-free 0.243 |
| 1NBX Streptavidin Mutant Y43A at 1.70A Resolution Deposited 2002-12-04 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：Y43A Mutation：Y43A Mutation：Y43A Mutation：Y43A | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.273 |
| 1NC9 STREPTAVIDIN MUTANT Y43A WITH IMINOBIOTIN AT 1.8A RESOLUTION Deposited 2002-12-05 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core strepavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core strepavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core strepavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core strepavidin, residues 13-139
|
Mutation：Y43A Mutation：Y43A Mutation：Y43A Mutation：Y43A | IMI 2-IMINOBIOTIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.266 |
| 1NDJ Streptavidin Mutant Y43F with Biotin at 1.81A Resolution Deposited 2002-12-09 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain B
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain C
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
Chain D
37–163（127 aa）
Fragment：core streptavidin, residues 13-139
|
Mutation：Y43F Mutation：Y43F Mutation：Y43F Mutation：Y43F | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG4000, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.81 Å R-free 0.312 |
| 1NQM Structure of Savm-W120K, streptavidin mutant Deposited 2003-01-22 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
24–159（136 aa）
Chain B
24–159（136 aa）
Chain C
24–159（136 aa）
Chain D
24–159（136 aa）
|
Mutation：W120K Mutation：W120K Mutation：W120K Mutation：W120K | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.45；293 K；25% PEG 6K, 0.3M sodium acetate, 0.1M cac. buffer, pH 6.45, VAPOR DIFFUSION, HANGING DROP, temperature 20K
|
Resolution 1.70 Å R-free 0.240 |
| 1PTS CRYSTAL STRUCTURE AND LIGAND BINDING STUDIES OF A SCREENED PEPTIDE COMPLEXED WITH STREPTAVIDIN Deposited 1992-07-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å |
| 1PTS CRYSTAL STRUCTURE AND LIGAND BINDING STUDIES OF A SCREENED PEPTIDE COMPLEXED WITH STREPTAVIDIN Deposited 1992-07-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å |
| 1RST COMPLEX BETWEEN STREPTAVIDIN AND THE STREP-TAG PEPTIDE Deposited 1995-10-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
38–163（126 aa）
Fragment：RESIDUES 13 - 139
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.227 |
| 1RSU COMPLEX BETWEEN STREPTAVIDIN AND THE STREP-TAG II PEPTIDE Deposited 1995-10-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
38–163（126 aa）
Fragment：RESIDUES 13 - 139
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.213 |
| 1RXH Crystal structure of streptavidin mutant L124R (M1) complexed with biotinyl p-nitroanilide (BNI) Deposited 2003-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Mutation：L124R, L324R Mutation：L124R, L324R | BNI 5-(2-OXO-HEXAHYDRO-THIENO[3,4-D]IMIDAZOL-6-YL)-PENTANOIC ACID (4-NITRO-PHENYL)-AMIDE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å R-free 0.309 |
| 1RXJ Crystal structure of streptavidin mutant (M2) where the L3,4 loop was replace by that of avidin Deposited 2003-12-18 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | BNI 5-(2-OXO-HEXAHYDRO-THIENO[3,4-D]IMIDAZOL-6-YL)-PENTANOIC ACID (4-NITRO-PHENYL)-AMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；PEG 4000, 0.1M NaAc, 0.1M NaCac, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.14 Å R-free 0.200 |
| 1RXK crystal structure of streptavidin mutant (M3) a combination of M1+M2 Deposited 2003-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–159（122 aa）
Chain B
38–159（122 aa）
|
Mutation：L124R Mutation：L124R | BNI 5-(2-OXO-HEXAHYDRO-THIENO[3,4-D]IMIDAZOL-6-YL)-PENTANOIC ACID (4-NITRO-PHENYL)-AMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；1.5M AS, 0.1M Tris-HCl, pH 8.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.239 |
| 1SLD STREPTAVIDIN, PH 7.5, BOUND TO CYCLIC DISULFIDE-BONDED PEPTIDE LIGAND AC-CHPQFC-NH2 Deposited 1995-03-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.50 Å R-free 0.220 |
| 1SLE STREPTAVIDIN, PH 5.0, BOUND TO CYCLIC PEPTIDE AC-CHPQGPPC-NH2 Deposited 1995-03-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5；pH 5.0
|
Resolution 2.00 Å R-free 0.233 |
| 1SLF APOSTREPTAVIDIN, PH 5.6, TWO MOLECULES OF (SO4)2 BOUND AT THE BIOTIN BINDING SITE Deposited 1995-03-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | SO4 SULFATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；pH 5.6
|
Resolution 1.76 Å R-free 0.202 |
| 1SLG STREPTAVIDIN, PH 5.6, BOUND TO PEPTIDE FCHPQNT Deposited 1995-03-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；pH 5.6
|
Resolution 1.76 Å R-free 0.222 |
| 1SRE CRYSTALLOGRAPHIC AND THERMODYNAMIC COMPARISON OF NATURAL AND SYNTHETIC LIGANDS BOUND TO STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | HAB 2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.78 Å |
| 1SRE CRYSTALLOGRAPHIC AND THERMODYNAMIC COMPARISON OF NATURAL AND SYNTHETIC LIGANDS BOUND TO STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | HAB 2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID × 8 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.78 Å |
| 1SRF STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | MTB 2-((3'-TERTBUTYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å |
| 1SRG STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | MHB 2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 1SRG STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | MHB 2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID × 8 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 1SRH STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | MOB 2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å |
| 1SRI STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | DMB 2-((3',5'-DIMETHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.65 Å |
| 1SRI STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | DMB 2-((3',5'-DIMETHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID × 8 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.65 Å |
| 1SRJ STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN Deposited 1994-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
Chain B
37–157（121 aa）
|
Not recorded | NAB 2-((4'-HYDROXYNAPHTHYL)-AZO)BENZOIC ACID × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 1STP STRUCTURAL ORIGINS OF HIGH-AFFINITY BIOTIN BINDING TO STREPTAVIDIN Deposited 1992-03-12 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–183（159 aa）
|
Not recorded | BTN BIOTIN × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.60 Å |
| 1STR STREPTAVIDIN DIMERIZED BY DISULFIDE-BONDED PEPTIDE AC-CHPQNT-NH2 DIMER Deposited 1995-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å R-free 0.233 |
| 1STS STREPTAVIDIN DIMERIZED BY DISULFIDE-BONDED PEPTIDE FCHPQNT-NH2 DIMER Deposited 1995-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.95 Å R-free 0.238 |
| 1SWA APO-CORE-STREPTAVIDIN AT PH 4.5 Deposited 1997-03-02 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain B
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain C
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain D
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN WAS CRYSTALLIZED FROM 47% MPD (PH 4.5)
|
Resolution 1.90 Å R-free 0.256 |
| 1SWB APO-CORE-STREPTAVIDIN AT PH 7.5 Deposited 1997-03-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain B
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain C
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain D
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN WAS CRYSTALLIZED FROM 48% MPD (2-METHYL-PENTANE-2,4-DIOLE, PH 4.5), 5.5H SOAKING IN 0.1M HEPES BUFFER PH 7.5
|
Resolution 1.85 Å R-free 0.253 |
| 1SWC APO-CORE-STREPTAVIDIN AT PH 4.5 Deposited 1997-03-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain B
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain C
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain D
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN WAS CRYSTALLIZED FROM 60% MPD (2-METHYL-PENTANE-2,4-DIOLE, PH 4.5), SOAKING IN 20 MM SODIUM ACETATE BUFFER PH 4.5
|
Resolution 1.80 Å R-free 0.232 |
| 1SWD APO-CORE-STREPTAVIDIN IN COMPLEX WITH BIOTIN (TWO UNOCCUPIED BINDING SITES) AT PH 4.5 Deposited 1997-03-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain B
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain C
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain D
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
|
Not recorded | BTN BIOTIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN-BIOTIN COMPLEX WAS CO-CRYSTALLIZED FROM 50% MPD (2-METHYL-PENTANE-2,4-DIOLE, PH 4.5) WITH 1.2M EXCESS OF BIOTIN
|
Resolution 1.90 Å R-free 0.328 |
| 1SWE APO-CORE-STREPTAVIDIN IN COMPLEX WITH BIOTIN AT PH 4.5 Deposited 1997-03-04 | Different construct Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain B
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain C
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
Chain D
37–163（127 aa）
Fragment：CORE, RESIDUES 13 - 139
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN-BIOTIN COMPLEX WAS CO-CRYSTALLIZED FROM 50% MPD (2-METHYL-PENTANE-2,4-DIOLE, PH 4.5) WITH 2.5M EXCESS OF BIOTIN
|
Resolution 2.06 Å R-free 0.266 |
| 1SWF CIRCULAR PERMUTED STREPTAVIDIN E51/A46 Deposited 1997-04-23 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
75–163（89 aa）
Chain B
75–163（89 aa）
Chain C
75–163（89 aa）
Chain D
75–163（89 aa）
|
Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN WAS CRYSTALLIZED FROM 52% MPD (PH 4.5).
|
Resolution 2.00 Å R-free 0.288 |
| 1SWF CIRCULAR PERMUTED STREPTAVIDIN E51/A46 Deposited 1997-04-23 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
75–163（89 aa）
Chain B
75–163（89 aa）
Chain C
75–163（89 aa）
Chain D
75–163（89 aa）
|
Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN WAS CRYSTALLIZED FROM 52% MPD (PH 4.5).
|
Resolution 2.00 Å R-free 0.288 |
| 1SWG CIRCULAR PERMUTED STREPTAVIDIN E51/A46 IN COMPLEX WITH BIOTIN Deposited 1997-07-12 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
75–178（104 aa）
Chain B
75–178（104 aa）
Chain C
75–178（104 aa）
Chain D
75–178（104 aa）
|
Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN (12MG/ML, 10MM BIOTIN) WAS CRYSTALLIZED FROM 52% MPD (PH 4.5)
|
Resolution 1.80 Å R-free 0.245 |
| 1SWG CIRCULAR PERMUTED STREPTAVIDIN E51/A46 IN COMPLEX WITH BIOTIN Deposited 1997-07-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
75–178（104 aa）
Chain B
75–178（104 aa）
|
Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; | BTN BIOTIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN (12MG/ML, 10MM BIOTIN) WAS CRYSTALLIZED FROM 52% MPD (PH 4.5)
|
Resolution 1.80 Å R-free 0.245 |
| 1SWG CIRCULAR PERMUTED STREPTAVIDIN E51/A46 IN COMPLEX WITH BIOTIN Deposited 1997-07-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
75–178（104 aa）
Chain D
75–178（104 aa）
|
Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; Mutation：;DELETION OF SURFACE LOOP RESIDUES 45 - 50 FROM THE SEQUENCE. THE OLD N- AND C-TERMINI (S139, A13, RESPECTIVELY) ARE CONNECTED INTRODUCING THE FOUR ADDITIONAL RESIDUES GGGS ; | BTN BIOTIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；PROTEIN (12MG/ML, 10MM BIOTIN) WAS CRYSTALLIZED FROM 52% MPD (PH 4.5)
|
Resolution 1.80 Å R-free 0.245 |
| 1SWH CORE-STREPTAVIDIN MUTANT W79F AT PH 4.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W79F Mutation：W79F Mutation：W79F Mutation：W79F | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；pH 4.5
|
Resolution 1.70 Å R-free 0.244 |
| 1SWJ CORE-STREPTAVIDIN MUTANT W79F AT PH 4.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W79F Mutation：W79F Mutation：W79F Mutation：W79F | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；pH 4.5
|
Resolution 2.00 Å R-free 0.281 |
| 1SWK CORE-STREPTAVIDIN MUTANT W79F IN COMPLEX WITH BIOTIN AT PH 4.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W79F Mutation：W79F Mutation：W79F Mutation：W79F | BTN BIOTIN × 3 BTQ EPI-BIOTIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；pH 4.5
|
Resolution 2.00 Å R-free 0.238 |
| 1SWL CORE-STREPTAVIDIN MUTANT W108F AT PH 7.0 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W108F Mutation：W108F Mutation：W108F Mutation：W108F | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.0
|
Resolution 1.80 Å R-free 0.309 |
| 1SWN CORE-STREPTAVIDIN MUTANT W108F IN COMPLEX WITH BIOTIN AT PH 7.0 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W108F Mutation：W108F Mutation：W108F Mutation：W108F | BTN BIOTIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.0
|
Resolution 2.20 Å R-free 0.268 |
| 1SWO CORE-STREPTAVIDIN MUTANT W120F AT PH 7.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W120F Mutation：W120F Mutation：W120F Mutation：W120F | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 1.95 Å R-free 0.257 |
| 1SWP CORE-STREPTAVIDIN MUTANT W120F IN COMPLEX WITH BIOTIN AT PH 7.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W120F Mutation：W120F Mutation：W120F Mutation：W120F | BTN BIOTIN × 3 BTQ EPI-BIOTIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.00 Å R-free 0.329 |
| 1SWQ CORE-STREPTAVIDIN MUTANT W120A AT PH 7.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W120A Mutation：W120A Mutation：W120A Mutation：W120A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 1.90 Å R-free 0.259 |
| 1SWR CORE-STREPTAVIDIN MUTANT W120A IN COMPLEX WITH BIOTIN AT PH 7.5 Deposited 1998-01-27 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：W120A Mutation：W120A Mutation：W120A Mutation：W120A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 1.90 Å R-free 0.264 |
| 1SWT CORE-STREPTAVIDIN MUTANT D128A IN COMPLEX WITH BIOTIN AT PH 4.5 Deposited 1998-10-22 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Mutation：D128A Mutation：D128A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；INCUBATED IN 2.5 M BIOTIN/HOH, COCRYSTALLIZED IN 52% MPD (PH 4.5)
|
Resolution 2.00 Å R-free 0.308 |
| 1SWU STREPTAVIDIN MUTANT Y43F Deposited 1998-10-12 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Mutation：Y43F Mutation：Y43F Mutation：Y43F Mutation：Y43F | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；pH 4.5
|
Resolution 1.14 Å R-free 0.157 |
| 1VWA STREPTAVIDIN-FSHPQNT Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；SYNTHETIC MOTHER LIQUOR = 50 % SATURATED AMMONIUM SULFATE, 50 % 0.1 M POTASSIUM ACETATE., pH 4.0
|
Resolution 1.85 Å R-free 0.259 |
| 1VWB STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 11.8 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 11.8；SYNTHETIC MOTHER LIQUOR = 50 % SATURATED AMMONIUM SULFATE, 0.1 M CAPS ADJUSTED TO PH 11.8.
|
Resolution 1.82 Å R-free 0.239 |
| 1VWC STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 2.0 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.0.
|
Resolution 1.86 Å R-free 0.209 |
| 1VWD STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 3.0 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.0.
|
Resolution 1.87 Å R-free 0.209 |
| 1VWE STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 3.6 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.6；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.6.
|
Resolution 1.50 Å R-free 0.246 |
| 1VWF STREPTAVIDIN COMPLEXED WITH CYCLO-AC-[CHPQGPPC]-NH2 MONOMER, PH 3.67 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.67；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.67.
|
Resolution 1.92 Å R-free 0.236 |
| 1VWG STREPTAVIDIN COMPLEXED WITH THE HEAD-TO-TAIL DISULFIDE-BONDED PEPTIDE DIMER OF CYCLO-AC-[CHPQGPPC]-NH2, PH 2.5 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 2.5.
|
Resolution 1.46 Å R-free 0.237 |
| 1VWH STREPTAVIDIN COMPLEXED WITH THE HEAD-TO-TAIL DISULFIDE-BONDED PEPTIDE DIMER OF CYCLO-AC-[CHPQGPPC]-NH2, PH 3.5 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.5.
|
Resolution 1.48 Å R-free 0.239 |
| 1VWI STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 1.5, I222 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.5.
|
Resolution 1.50 Å R-free 0.235 |
| 1VWI STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 1.5, I222 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 16 PDB declaration: hexadecameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.5.
|
Resolution 1.50 Å R-free 0.235 |
| 1VWI STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 1.5, I222 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.5.
|
Resolution 1.50 Å R-free 0.235 |
| 1VWJ STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 2.5, I222 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.5
|
Resolution 1.45 Å R-free 0.237 |
| 1VWJ STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 2.5, I222 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 16 PDB declaration: hexadecameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.5
|
Resolution 1.45 Å R-free 0.237 |
| 1VWK STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 3.0.
|
Resolution 1.45 Å R-free 0.240 |
| 1VWL STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 3.5, I222 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.5.
|
Resolution 1.45 Å R-free 0.244 |
| 1VWM STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 4.2 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.2；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 4.2.
|
Resolution 1.60 Å R-free 0.243 |
| 1VWN STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 4.8 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.8；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 4.8.
|
Resolution 1.85 Å R-free 0.250 |
| 1VWO STREPTAVIDIN COMPLEXED WITH CYCLO-AC-[CHPQGPPC]-NH2 MONOMER, PH 2.85 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.85；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.85.
|
Resolution 1.65 Å R-free 0.228 |
| 1VWP STREPTAVIDIN COMPLEXED WITH CYCLO-AC-[CHPQGPPC]-NH2 MONOMER, PH 2.5 Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.5.
|
Resolution 1.75 Å R-free 0.235 |
| 1VWQ STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 2.5, I4122 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.5.
|
Resolution 1.70 Å R-free 0.223 |
| 1VWR STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 3.5, I4122 COMPLEX Deposited 1997-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
|
Not recorded | LEA PENTANOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.5.
|
Resolution 1.50 Å R-free 0.246 |
| 2BC3 T7-tagged full-length streptavidin Deposited 2005-10-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | GOL GLYCEROL × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.5；293 K；25% Ammonium Sulfate, 0.1M NaAcetate pH4.5, VAPOR DIFFUSION, temperature 293K
|
Resolution 1.54 Å R-free 0.243 |
| 2F01 Epi-biotin complex with core streptavidin Deposited 2005-11-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Not recorded | BTN BIOTIN × 4 BTQ EPI-BIOTIN × 4 GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.5；277 K；38% saturated ammonium sulfate, 0.1 M sodium acetate, pH 4.5, 0.2 M sodium chloride, VAPOR DIFFUSION, temperature 277K
|
Resolution 0.85 Å R-free 0.174 |
| 2G5L Streptavidin in complex with Nanotag Deposited 2006-02-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
37–163（127 aa）
Fragment：residues 13-139
Chain B
37–163（127 aa）
Fragment：residues 13-139
|
Not recorded | SO4 SULFATE ION × 4 GOL GLYCEROL × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.15 Å R-free 0.172 |
| 2GH7 Epi-biotin complex with core streptavidin Deposited 2006-03-26 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Not recorded | BTN BIOTIN × 4 BTQ EPI-BIOTIN × 4 GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；Protein solution - 10 mg/mL, 10mM Tris Hl, pH 7.0
Reservoir - 38% saturate ammonium sulfate, 0.1 M sodium acetate, pH 4.5,0.2 M NaCl , VAPOR DIFFUSION
|
Resolution 1.00 Å R-free 0.152 |
| 2IZA APOSTREPTAVIDIN PH 2.00 I4122 STRUCTURE Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–157（121 aa）
|
Not recorded | FMT FORMIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；SYNTHETIC MOTHER LIQUOR = 75% SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.00. COMPLEX PRODUCED BY SOAKING STREPTAVIDIN-2-IMINOBIOTIN CO-CRYSTAL.
|
Resolution 1.46 Å R-free 0.220 |
| 2IZB APOSTREPTAVIDIN PH 3.12 I4122 STRUCTURE Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–158（122 aa）
|
Not recorded | SO4 SULFATE ION × 4 FMT FORMIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.12；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM ACETATE ADJUSTED TO PH 3.12. COMPLEX PRODUCED BY SOAKING STREPTAVIDIN-2-IMINOBIOTIN CO-CRYSTAL.
|
Resolution 1.20 Å R-free 0.235 |
| 2IZC APOSTREPTAVIDIN PH 2.0 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | NA SODIUM ION × 4 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.0.
|
Resolution 1.40 Å R-free 0.241 |
| 2IZC APOSTREPTAVIDIN PH 2.0 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | NA SODIUM ION × 8 CL CHLORIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.0.
|
Resolution 1.40 Å R-free 0.241 |
| 2IZD APOSTREPTAVIDIN pH 3.0 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | SO4 SULFATE ION × 2 CL CHLORIDE ION × 4 IOD IODIDE ION × 2 NH4 AMMONIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.0.
|
Resolution 1.60 Å R-free 0.252 |
| 2IZD APOSTREPTAVIDIN pH 3.0 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | SO4 SULFATE ION × 4 CL CHLORIDE ION × 8 IOD IODIDE ION × 4 NH4 AMMONIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.0.
|
Resolution 1.60 Å R-free 0.252 |
| 2IZE APOSTREPTAVIDIN PH 3.08 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | NA SODIUM ION × 2 CL CHLORIDE ION × 4 FMT FORMIC ACID × 4 NH4 AMMONIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.08；SYNTHETIC MOTHER LIQUOR = 50 % SATURATED AMMONIUM SULFATE, 50 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 3.08.
|
Resolution 1.57 Å R-free 0.252 |
| 2IZE APOSTREPTAVIDIN PH 3.08 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | NA SODIUM ION × 4 CL CHLORIDE ION × 8 FMT FORMIC ACID × 8 NH4 AMMONIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.08；SYNTHETIC MOTHER LIQUOR = 50 % SATURATED AMMONIUM SULFATE, 50 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 3.08.
|
Resolution 1.57 Å R-free 0.252 |
| 2IZF STREPTAVIDIN-BIOTIN PH 4.0 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 4.0.
|
Resolution 1.58 Å R-free 0.200 |
| 2IZG STREPTAVIDIN-BIOTIN PH 2.0 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.0.
|
Resolution 1.36 Å R-free 0.235 |
| 2IZH STREPTAVIDIN-BIOTIN PH 10.44 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 10.44；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 50.0 MM CAPS ADJUSTED TO PH 10.44.
|
Resolution 1.36 Å R-free 0.227 |
| 2IZI STREPTAVIDIN-BIOTIN PH 2.53 I4122 STRUCTURE Deposited 1997-08-13 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–159（123 aa）
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.53；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M SODIUM ACETATE ADJUSTED TO PH 2.53. COMPLEX PRODUCED BY SOAKING STREPTAVIDIN-2-IMINOBIOTIN CO-CRYSTAL.
|
Resolution 1.50 Å R-free 0.246 |
| 2IZJ STREPTAVIDIN-BIOTIN PH 3.50 I4122 STRUCTURE Deposited 1997-08-13 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–159（123 aa）
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.5；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25 % 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.50. COMPLEX PRODUCED BY SOAKING STREPTAVIDIN-2-IMINOBIOTIN CO-CRYSTAL.
|
Resolution 1.30 Å R-free 0.222 |
| 2IZK STREPTAVIDIN-GLYCOLURIL PH 2.58 I4122 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–159（123 aa）
|
Not recorded | ACT ACETATE ION × 4 SO4 SULFATE ION × 4 GLL GLYCOLURIL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.58；SYNTHETIC MOTHER LIQUOR = 75 % SATURATED AMMONIUM SULFATE, 25% 1.0M POTASSIUM ACETATE ADJUSTED TO PH 2.58. COMPLEX PRODUCED BY SOAKING STREPTAVIDIN-2-IMINOBIOTIN CO-CRYSTAL.
|
Resolution 1.30 Å R-free 0.202 |
| 2IZL STREPTAVIDIN-2-IMINOBIOTIN PH 7.3 I222 COMPLEX Deposited 1997-08-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
37–159（123 aa）
Chain D
37–159（123 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.3；SYNTHETIC MOTHER LIQUOR = 75% SATURATED AMMONIUM SULFATE, 25% 1M TRIS ADJUSTED TO PH 7.3
|
Resolution 1.48 Å R-free 0.211 |
| 2QCB T7-tagged full-length streptavidin complexed with ruthenium ligand Deposited 2007-06-19 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112K | KYS N-(4-{[(2-AMINOETHYL)AMINO]SULFONYL}PHENYL)-5-[(3AS,4S,6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]PENTANAMIDE-(1,2,3,4,5,6-ETA)-BENZENE-CHLORO-RUTHENIUM(III) × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；protein, 26 mg/ml in water.
4-5x molar excess of ligand.
reservoir, 1.0 M sodium citrate, 0.1 M cacodylate buffer, pH 6.5 , VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.65 Å R-free 0.187 |
| 2RTA APOSTREPTAVIDIN, PH 2.97, SPACE GROUP I4122 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–159（135 aa）
|
Not recorded | SO4 SULFATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.97；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.97.
|
Resolution 1.39 Å R-free 0.238 |
| 2RTB APOSTREPTAVIDIN, PH 3.32, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | NA SODIUM ION × 2 ACT ACETATE ION × 2 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.32；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.32.
|
Resolution 1.50 Å R-free 0.258 |
| 2RTC APOSTREPTAVIDIN, PH 3.60, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | SO4 SULFATE ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.6；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, SODIUM FORMATE ADJUSTED TO PH 3.60.
|
Resolution 1.50 Å R-free 0.265 |
| 2RTD STREPTAVIDIN-BIOTIN COMPLEX, PH 1.39, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.39；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, SODIUM FORMATE ADJUSTED TO PH 1.39.
|
Resolution 1.65 Å R-free 0.236 |
| 2RTE STREPTAVIDIN-BIOTIN COMPLEX, PH 1.90, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.9；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, SODIUM FORMATE ADJUSTED TO PH 1.90.
|
Resolution 1.50 Å R-free 0.220 |
| 2RTF STREPTAVIDIN-BIOTIN COMPLEX, PH 2.00, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；ROOM TEMPERATURE, PH 2.0. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE, 0.99 MM BIOTIN, 170 MM 2-IMINOBIOTIN, ADJUSTED TO PH 2.00.
|
Resolution 1.47 Å R-free 0.230 |
| 2RTG STREPTAVIDIN-BIOTIN COMPLEX, PH 2.40, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | CL CHLORIDE ION × 2 BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.4；ROOM TEMPERATURE, PH 2.0. SYNTHETIC MOTHER LIQUOR, 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE, 0.2 MM BIOTIN, 25 MM 2-IMINOBIOTIN, ADJUSTED TO PH 2.40.
|
Resolution 1.39 Å R-free 0.223 |
| 2RTH STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | ACT ACETATE ION × 4 GLL GLYCOLURIL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；ROOM TEMPERATURE, PH 2.50. SYNTHETIC MOTHER LIQUOR, 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M POTASSIUM ACETATE, ADJUSTED TO PH 2.50.
|
Resolution 1.56 Å R-free 0.269 |
| 2RTH STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | ACT ACETATE ION × 8 GLL GLYCOLURIL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；ROOM TEMPERATURE, PH 2.50. SYNTHETIC MOTHER LIQUOR, 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M POTASSIUM ACETATE, ADJUSTED TO PH 2.50.
|
Resolution 1.56 Å R-free 0.269 |
| 2RTI STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | GLL GLYCOLURIL × 4 FMT FORMIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.9；SYNTHETIC MOTHER LIQUOR, 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.90.
|
Resolution 1.40 Å R-free 0.232 |
| 2RTI STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | GLL GLYCOLURIL × 8 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.9；SYNTHETIC MOTHER LIQUOR, 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.90.
|
Resolution 1.40 Å R-free 0.232 |
| 2RTJ STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I4122 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–159（135 aa）
|
Not recorded | GLL GLYCOLURIL × 4 FMT FORMIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.5；ROOM TEMPERATURE, PH 2.50. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE ADJUSTED TO PH 2.50.
|
Resolution 1.40 Å R-free 0.221 |
| 2RTK STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.58, SPACE GROUP I4122 PREPARED FROM AN APOSTREPTAVIDIN CRYSTAL Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–159（135 aa）
|
Not recorded | ACT ACETATE ION × 4 SO4 SULFATE ION × 4 GLL GLYCOLURIL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.9；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.90.
|
Resolution 1.82 Å R-free 0.276 |
| 2RTL STREPTAVIDIN-2-IMINOBIOTIN-SULFATE COMPLEX, PH 2.50, SPACE GROUP I4122 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–159（135 aa）
|
Not recorded | SO4 SULFATE ION × 4 IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1.9；SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE ADJUSTED TO PH 1.90.
|
Resolution 1.41 Å R-free 0.234 |
| 2RTM STREPTAVIDIN-2-IMINOBIOTIN-SULFATE COMPLEX, PH 3.50, SPACE GROUP I4122 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–159（135 aa）
|
Not recorded | SO4 SULFATE ION × 4 IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.5；ROOM TEMPERATURE, PH 3.50. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 3.50.
|
Resolution 1.30 Å R-free 0.238 |
| 2RTN STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 2.0, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；ROOM TEMPERATURE, PH 2.00. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE, SATURATED IN 2-IMINOBIOTIN, PH ADJUSTED TO PH 2.00.
|
Resolution 1.80 Å R-free 0.200 |
| 2RTN STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 2.0, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；ROOM TEMPERATURE, PH 2.00. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M SODIUM FORMATE, SATURATED IN 2-IMINOBIOTIN, PH ADJUSTED TO PH 2.00.
|
Resolution 1.80 Å R-free 0.200 |
| 2RTO STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 2.6, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.6；ROOM TEMPERATURE, PH 2.60. SYNTHETIC MOTHER LIQUOR OF 50% SATURATED AMMONIUM SULFATE, 50% 1 M SODIUM FORMATE, 170 MM 2-IMINOBIOTIN, PH ADJUSTED TO 2.6.
|
Resolution 1.58 Å R-free 0.253 |
| 2RTO STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 2.6, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2.6；ROOM TEMPERATURE, PH 2.60. SYNTHETIC MOTHER LIQUOR OF 50% SATURATED AMMONIUM SULFATE, 50% 1 M SODIUM FORMATE, 170 MM 2-IMINOBIOTIN, PH ADJUSTED TO 2.6.
|
Resolution 1.58 Å R-free 0.253 |
| 2RTP STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 3.25, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.25；ROOM TEMPERATURE, PH 3.25. SYNTHETIC MOTHER LIQUOR OF 50% SATURATED AMMONIUM SULFATE, 50% 1 M POTASSIUM ACETATE, 170 MM 2-IMINOBIOTIN, PH ADJUSTED TO 3.25
|
Resolution 1.50 Å R-free 0.243 |
| 2RTP STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 3.25, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.25；ROOM TEMPERATURE, PH 3.25. SYNTHETIC MOTHER LIQUOR OF 50% SATURATED AMMONIUM SULFATE, 50% 1 M POTASSIUM ACETATE, 170 MM 2-IMINOBIOTIN, PH ADJUSTED TO 3.25
|
Resolution 1.50 Å R-free 0.243 |
| 2RTQ STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 3.25, SPACE GROUP I222, CRYSTALLIZED FROM 4.3 M AMMONIUM SULFATE Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.25；ROOM TEMPERATURE, PH 3.25. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1 M POTASSIUM ACETATE, 25 MM 2-IMINOBIOTIN, PH ADJUSTED TO 3.25
|
Resolution 1.39 Å R-free 0.243 |
| 2RTQ STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 3.25, SPACE GROUP I222, CRYSTALLIZED FROM 4.3 M AMMONIUM SULFATE Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3.25；ROOM TEMPERATURE, PH 3.25. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1 M POTASSIUM ACETATE, 25 MM 2-IMINOBIOTIN, PH ADJUSTED TO 3.25
|
Resolution 1.39 Å R-free 0.243 |
| 2RTR STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 4.0, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；ROOM TEMPERATURE, PH 4.00. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 4.0.
|
Resolution 1.62 Å R-free 0.234 |
| 2RTR STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 4.0, SPACE GROUP I222 Deposited 1997-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain B
25–159（135 aa）
Chain D
25–159（135 aa）
|
Not recorded | IMI 2-IMINOBIOTIN × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；ROOM TEMPERATURE, PH 4.00. SYNTHETIC MOTHER LIQUOR OF 75% SATURATED AMMONIUM SULFATE, 25% 1.0 M POTASSIUM ACETATE ADJUSTED TO PH 4.0.
|
Resolution 1.62 Å R-free 0.234 |
| 2WPU Chaperoned ruthenium metallodrugs that recognize telomeric DNA Deposited 2009-08-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | KYT (3AS,4S,6AR)-4-(5-((3R,4R)-3,4-DIAMINOPYRROLIDIN-1-YL)-5-OXOPENTYL)TETRAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-2(3H)-ONE-P-CYMENE-CHLORO-RUTHENIUM(III) × 4 SO4 SULFATE ION × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；298 K；PROTEIN, 26 MG/ML IN WATER. RESERVOIR, 2.0 M AMMONIUM SULFATE, 0.1 M SODIUM ACETATE BUFFER, PH 4.0 , VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K. LIGAND SOAKING CONDITIONS: LIGAND, 10 MM K2OSO2(OH)4 IN 3.0 M AMMONIUM SULFATE, 0.1 SODIUM ACETATE BUFFER, PH 4.0, CRYO, 1.5 M AMMONIUM SULFATE, 0.1 SODIUM ACETATE BUFFER, PH 4.0
|
Resolution 1.92 Å R-free 0.198 |
| 2Y3E Traptavidin, apo-form Deposited 2010-12-20 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；12% PEG 8000, 9% ETHYLENE GLYCOL, 0.1 M HEPES PH 7.5
|
Resolution 1.45 Å R-free 0.178 |
| 2Y3F Traptavidin, biotin bound form Deposited 2010-12-20 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES | BTN BIOTIN × 4 GOL GLYCEROL × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；27% PEG 4000, 0.25M MGCL2, 0.1M TRIS-HCL PH 8.5
|
Resolution 1.49 Å R-free 0.151 |
| 3MG5 Core-streptavidin mutant F130L in complex with biotin Deposited 2010-04-05 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：CORE STREPTAVIDIN (RESIDUES 13-139)
Chain B
37–163（127 aa）
Fragment：CORE STREPTAVIDIN (RESIDUES 13-139)
Chain C
37–163（127 aa）
Fragment：CORE STREPTAVIDIN (RESIDUES 13-139)
Chain D
37–163（127 aa）
Fragment：CORE STREPTAVIDIN (RESIDUES 13-139)
|
Mutation：F154L Mutation：F154L Mutation：F154L Mutation：F154L | BTN BIOTIN × 4 GOL GLYCEROL × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1 M HEPES, pH 7.5, 16% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.30 Å R-free 0.178 |
| 3PK2 Artificial Transfer Hydrogenases for the Enantioselective Reduction of Cyclic Imines Deposited 2010-11-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112A | 4IR {N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(chloro)[(1,2,3,4,5-eta)-1,2,3,4,5-pentamethylcyclopentadienyl]iridium(III) × 4 IR3 IRIDIUM (III) ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；298 K；3.5 uL precipitation buffer (2.0 M ammonium sulfate, 0.1 M sodium acetate) mixed with 6.5 uL protein (26 mg/mL) and equilibrated against precipitation buffer, pH 4.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.90 Å R-free 0.204 |
| 3RDM Crystal structure of R7-2 streptavidin complexed with biotin/PEG Deposited 2011-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S, W108V, L110T, F29L, S52G, R53S | 1PE PENTAETHYLENE GLYCOL × 1 BTN BIOTIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；0.2 MgCl2, 0.1 Bis-Tris, pH 5.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.60 Å R-free 0.245 |
| 3RDM Crystal structure of R7-2 streptavidin complexed with biotin/PEG Deposited 2011-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S, W108V, L110T, F29L, S52G, R53S | 1PE PENTAETHYLENE GLYCOL × 4 BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；0.2 MgCl2, 0.1 Bis-Tris, pH 5.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.60 Å R-free 0.245 |
| 3RDO Crystal structure of R7-2 streptavidin complexed with biotin Deposited 2011-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S, W108V, L110T, F29L, S52G, R53S | BTN BIOTIN × 1 NI NICKEL (II) ION × 1 SO4 SULFATE ION × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1 M ammonium sulfate, 0.1 M Tris, pH 7.5, 20% PEG 1500, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.40 Å R-free 0.171 |
| 3RDQ Crystal structure of R7-2 streptavidin complexed with desthiobiotin Deposited 2011-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S, W108V, L110T, F29L, S52G, R53S | DTB 6-(5-METHYL-2-OXO-IMIDAZOLIDIN-4-YL)-HEXANOIC ACID × 1 NI NICKEL (II) ION × 1 NA SODIUM ION × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；0.1 M Na-acetate, pH 5.0, 2 M Na-formate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.60 Å R-free 0.190 |
| 3RDS Crystal structure of the refolded R7-2 streptavidin Deposited 2011-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S, W108V, L110T, F29L, S52G, R53S | 1PE PENTAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；25% PEG 1500, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.50 Å R-free 0.214 |
| 3RDS Crystal structure of the refolded R7-2 streptavidin Deposited 2011-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S, W108V, L110T, F29L, S52G, R53S | 1PE PENTAETHYLENE GLYCOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；25% PEG 1500, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.50 Å R-free 0.214 |
| 3RDU Crystal structure of R7-2 streptavidin complexed with PEG Deposited 2011-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,S52G,R53S | GOL GLYCEROL × 3 1PE PENTAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；10% PEG1000, 10% PEG8000, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.50 Å R-free 0.207 |
| 3RDU Crystal structure of R7-2 streptavidin complexed with PEG Deposited 2011-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,S52G,R53S | GOL GLYCEROL × 12 1PE PENTAETHYLENE GLYCOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；10% PEG1000, 10% PEG8000, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.50 Å R-free 0.207 |
| 3RDX Crystal structure of ligand-free R7-2 streptavidin Deposited 2011-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
Chain B
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,S52G,R53S Mutation：T90S,W108V,L110T,F29L,S52G,R53S | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；298 K；0.1 M Na acetate, pH 4.5, 3 M sodium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.278 |
| 3RDX Crystal structure of ligand-free R7-2 streptavidin Deposited 2011-04-02 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
Chain B
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,S52G,R53S Mutation：T90S,W108V,L110T,F29L,S52G,R53S | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；298 K；0.1 M Na acetate, pH 4.5, 3 M sodium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.278 |
| 3RE5 Crystal structure of R4-6 streptavidin Deposited 2011-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,R53S | 1PE PENTAETHYLENE GLYCOL × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.2 MgCl2, 0.1 HEPES, pH 7.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.95 Å R-free 0.231 |
| 3RE5 Crystal structure of R4-6 streptavidin Deposited 2011-04-02 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,R53S | 1PE PENTAETHYLENE GLYCOL × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.2 MgCl2, 0.1 HEPES, pH 7.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.95 Å R-free 0.231 |
| 3RE6 Crystal structure of R4-6 streptavidin Deposited 2011-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,R53S | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；18% PEG 8000, 0.1 M Na-cacodylate, pH 6.5, 0.2 M Ca-acetate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.82 Å R-free 0.234 |
| 3RE6 Crystal structure of R4-6 streptavidin Deposited 2011-04-02 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–164（128 aa）
Fragment：UNP Residues 37-164
|
Mutation：T90S,W108V,L110T,F29L,R53S | GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；18% PEG 8000, 0.1 M Na-cacodylate, pH 6.5, 0.2 M Ca-acetate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.82 Å R-free 0.234 |
| 3RY1 Wild-type core streptavidin at atomic resolution Deposited 2011-05-10 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Not recorded | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 3 MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；298 K；52% MPD, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.03 Å R-free 0.135 |
| 3RY2 Wild-type core streptavidin-biotin complex at atomic resolution Deposited 2011-05-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Not recorded | BTN BIOTIN × 4 GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；298 K；30% saturated ammonium sulfate, 0.1 M sodium acetate, 0.2 M sodium chloride, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 0.95 Å R-free 0.131 |
| 3T6F Biotin complex of Y54F core streptavidin Deposited 2011-07-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y54F Mutation：Y54F | BTN BIOTIN × 4 BSO BIOTIN-D-SULFOXIDE × 4 GOL GLYCEROL × 8 SO4 SULFATE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；60% saturated ammonium sulfate, 5% isopropanol (30% glycerol cryoprotectant), pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.22 Å R-free 0.151 |
| 3T6L Y54F mutant of core streptavidin Deposited 2011-07-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y54F | CL CHLORIDE ION × 4 EDO 1,2-ETHANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；293 K；2.5 M sodium chloride, 0.1 M sodium-potassium phosphate (30% ethylene glycol cryoprotectant), pH 6.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.30 Å R-free 0.160 |
| 3WYP Crystal structure of wild-type core streptavidin in complex with D-biotin/biotin-D-sulfoxide at 1.3 A resolution Deposited 2014-09-05 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
Chain C
37–163（127 aa）
Fragment：UNP residues 37-163
Chain D
37–163（127 aa）
Fragment：UNP residues 37-163
|
Not recorded | BTN BIOTIN × 2 GOL GLYCEROL × 10 BSO BIOTIN-D-SULFOXIDE × 2 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；293 K；0.2M ammonium sulfate, 0.1M sodium acetate trihydrate, 24% polyethylene glycol 4000, pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.30 Å R-free 0.179 |
| 3WYQ Crystal structure of the low-immunogenic core streptavidin mutant LISA-314 (Y22S/Y83S/R84K/E101D/R103K/E116N) at 1.0 A resolution Deposited 2014-09-05 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y22S/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/Y83S/R84K/E101D/R103K/E116N | BTN BIOTIN × 4 GOL GLYCEROL × 20 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；293 K；0.2M ammonium sulfate, 0.1M sodium acetate trihydrate, 24% polyethylene glycol 4000, pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.00 Å R-free 0.163 |
| 3WZN Crystal structure of the core streptavidin mutant V21 (Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N) complexed with biotin at 1.3 A resolution Deposited 2014-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N | BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；294 K；100 mM sodium acetate trihydrate, 2.0 M ammonium sulfate, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 1.30 Å R-free 0.207 |
| 3WZO Crystal structure of the core streptavidin mutant V21 (Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N) complexed with biotin long tail (BTNtail) at 1.5 A resolution Deposited 2014-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
Chain C
37–163（127 aa）
Fragment：UNP residues 37-163
Chain D
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N | ZOE 6-({5-[(3aS,4S,5S,6aR)-5-oxido-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)hexanoic acid × 4 GOL GLYCEROL × 3 CD CADMIUM ION × 9 P6G HEXAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；293 K；0.1 M cadmium chloride hydrate, 0.1 M sodium acetate trihydrate, 30%(v/v) PEG400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.50 Å R-free 0.236 |
| 3WZP Crystal structure of the core streptavidin mutant V21 (Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.2 A resolution Deposited 2014-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
Chain C
37–163（127 aa）
Fragment：UNP residues 37-163
Chain D
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N | ZOF 6-({5-[(2E,3aS,4S,6aR)-2-iminohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)hexanoic acid × 4 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M sodium citrate tribasic dehydrate, 0.1 M HEPES sodium, 35%(w/v) (+/-)-2-methyl-2, 4-pentandiol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.20 Å R-free 0.161 |
| 3WZQ Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.7 A resolution Deposited 2014-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
Chain C
37–163（127 aa）
Fragment：UNP residues 37-163
Chain D
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N | ZOF 6-({5-[(2E,3aS,4S,6aR)-2-iminohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)hexanoic acid × 4 P6G HEXAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；293 K；60 mM sodium cacodylate trihydrate, 27%(w/v) PEG300, pH 6.8, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.244 |
| 3X00 Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with bis iminobiotin long tail (Bis-IMNtail) at 1.3 A resolution Deposited 2014-10-09 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：UNP residues 37-163
Chain B
37–163（127 aa）
Fragment：UNP residues 37-163
Chain C
37–163（127 aa）
Fragment：UNP residues 37-163
Chain D
37–163（127 aa）
Fragment：UNP residues 37-163
|
Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N Mutation：Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N | ZOF 6-({5-[(2E,3aS,4S,6aR)-2-iminohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)hexanoic acid × 4 EDN ETHANE-1,2-DIAMINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.2 M sodium fluoride, 20% PEG3350, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.30 Å R-free 0.188 |
| 4BX5 cis-divalent streptavidin Deposited 2013-07-08 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain C
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain D
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | EDO 1,2-ETHANEDIOL × 4 PG4 TETRAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；2.5 % W/V POLYETHYLENE GLYCOL (PEG) 1000, 12.5 % W/V PEG 3350, 12.5 % V/V MPD, 30 MM OF ETHYLENE GLYCOL MIX (DI-ETHYLENEGLYCOL, TRI-ETHYLENEGLYCOL, TETRA-ETHYLENEGLYCOL, PENTA-ETHYLENEGLYCOL) AND 0.1 M MES/IMIDAZOLE PH 6.5, CORRESPONDING TO CONDITION E4 OF THE MORPHEUS SCREEN
|
Resolution 1.43 Å R-free 0.187 |
| 4BX6 trans-divalent streptavidin Deposited 2013-07-08 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain C
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain D
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；65% V/V 2-METHYL-2, 4-PENTANEDIOL (MPD), 0.1 M 2-(N-MORPHOLINO)ETHANESULFONIC ACID (MES) PH 6.0. CRYSTALS WERE OBTAINED BY THE SITTING-DROP VAPOR-DIFFUSION METHOD AT 291 K AND REACHED A MAXIMUM SIZE AFTER 10 DAYS AND WERE HARVESTED SOON AFTER
|
Resolution 1.59 Å R-free 0.187 |
| 4BX7 trans-divalent streptavidin bound to biotin-4-fluorescein Deposited 2013-07-08 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Mutation：YES | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 B4F biotin-4-fluorescein × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；277 K；65% V/V MPD, 0.1 M MES PH 4.0. CRYSTALS WERE OBTAINED BY THE SITTING-DROP VAPOR-DIFFUSION METHOD AT 277 K, REACHED A MAXIMUM SIZE AFTER 14 DAYS AND WERE HARVESTED SOON AFTER
|
Resolution 2.26 Å R-free 0.237 |
| 4CPE Wild-type streptavidin in complex with love-hate ligand 1 (LH1) Deposited 2014-02-06 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Not recorded | LUV (3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4- d]imidazolidin-4-yl]-N-{2-[(2,6- diphenylphenyl)formamido]ethyl}pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；75% SATURATED AMMONIUM SULPHATE, 25% 1M SODIUM ACETATE PH4.5. SITTING DROP
|
Resolution 1.06 Å R-free 0.153 |
| 4CPF Wild-type streptavidin in complex with love-hate ligand 3 (LH3) Deposited 2014-02-06 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Not recorded | LH3 methyl 4-(2-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H- thieno[3,4-d]imidazolidin-4-yl]pentanehydrazido}-3- [4-(methoxycarbonyl)phenyl]phenyl)benzoate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；75% SATURATED AMMONIUM SULPHATE, 25% 1M SODIUM ACETATE PH4.5. SITTING DROP
|
Resolution 1.14 Å R-free 0.165 |
| 4CPH trans-divalent streptavidin with love-hate ligand 4 Deposited 2014-02-06 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain C
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain D
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | LH4 5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4- d]imidazolidin-4-yl]-N'-{2,6-bis[4-(morpholine-4- sulfonyl)phenyl]phenyl}pentanehydrazide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；75% AMMONIUM SULPHATE, 25% SODIUM ACETATE PH4.5. SITTING DROP
|
Resolution 1.64 Å R-free 0.232 |
| 4CPI streptavidin A86D mutant with love-hate ligand 4 Deposited 2014-02-06 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain D
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | LH4 5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4- d]imidazolidin-4-yl]-N'-{2,6-bis[4-(morpholine-4- sulfonyl)phenyl]phenyl}pentanehydrazide × 4 PEG DI(HYDROXYETHYL)ETHER × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；CONDITION A9 OF THE MORPHEUS SCREEN: 0.1 M BICINE/TRIZMA BASE PH 8.5, 10% W/V POLYETHYLENE GLYCOL 20,000, 20% V/V POLYETHYLENE GLYCOL MONOMETHYL ETHER 550, 30 MM MAGNESIUM CHLORIDE AND 30 MM CALCIUM CHLORIDE. SITTING DROP.
|
Resolution 1.54 Å R-free 0.181 |
| 4CPI streptavidin A86D mutant with love-hate ligand 4 Deposited 2014-02-06 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain B
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | LH4 5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4- d]imidazolidin-4-yl]-N'-{2,6-bis[4-(morpholine-4- sulfonyl)phenyl]phenyl}pentanehydrazide × 4 PEG DI(HYDROXYETHYL)ETHER × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；CONDITION A9 OF THE MORPHEUS SCREEN: 0.1 M BICINE/TRIZMA BASE PH 8.5, 10% W/V POLYETHYLENE GLYCOL 20,000, 20% V/V POLYETHYLENE GLYCOL MONOMETHYL ETHER 550, 30 MM MAGNESIUM CHLORIDE AND 30 MM CALCIUM CHLORIDE. SITTING DROP.
|
Resolution 1.54 Å R-free 0.181 |
| 4CPI streptavidin A86D mutant with love-hate ligand 4 Deposited 2014-02-06 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
37–163（127 aa）
Fragment：RESIDUES 37-163
Chain D
37–163（127 aa）
Fragment：RESIDUES 37-163
|
Mutation：YES Mutation：YES | LH4 5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4- d]imidazolidin-4-yl]-N'-{2,6-bis[4-(morpholine-4- sulfonyl)phenyl]phenyl}pentanehydrazide × 4 PEG DI(HYDROXYETHYL)ETHER × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；CONDITION A9 OF THE MORPHEUS SCREEN: 0.1 M BICINE/TRIZMA BASE PH 8.5, 10% W/V POLYETHYLENE GLYCOL 20,000, 20% V/V POLYETHYLENE GLYCOL MONOMETHYL ETHER 550, 30 MM MAGNESIUM CHLORIDE AND 30 MM CALCIUM CHLORIDE. SITTING DROP.
|
Resolution 1.54 Å R-free 0.181 |
| 4DNE Crystal structure of a triple-mutant of streptavidin in complex with desthiobiotin Deposited 2012-02-08 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
|
Mutation：E44V, S45T, V47R Mutation：E44V, S45T, V47R | DTB 6-(5-METHYL-2-OXO-IMIDAZOLIDIN-4-YL)-HEXANOIC ACID × 4 SO4 SULFATE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；10 mM MgSO4, 50 mM Na caodylate, 2M ammonium sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.88 Å R-free 0.219 |
| 4EKV Streptavidin 8-aa-loop H127C mutein with reversible biotin binding Deposited 2012-04-09 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–183（159 aa）
|
Mutation：H151C | BTN BIOTIN × 4 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；50% Tacsimate, 10% glycerol, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.225 |
| 4GD9 Circular Permuted Streptavidin N49/G48 Deposited 2012-07-31 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
73–163（91 aa）
Chain A
37–72（36 aa）
Chain B
73–163（91 aa）
Chain B
37–72（36 aa）
Chain C
73–163（91 aa）
Chain C
37–72（36 aa）
Chain D
73–163（91 aa）
Chain D
37–72（36 aa）
|
Not recorded | BTN BIOTIN × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.0 M ammonium phosphate, 0.1 M Tris-chloride, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.50 Å R-free 0.230 |
| 4GDA Circular Permuted Streptavidin A50/N49 Deposited 2012-07-31 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
74–163（90 aa）
Chain A
37–73（37 aa）
Chain B
74–163（90 aa）
Chain B
37–73（37 aa）
|
Not recorded | BTN BIOTIN × 4 GOL GLYCEROL × 6 SO4 SULFATE ION × 6 EOH ETHANOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；25% saturated ammonium sulfate, 0.1 M Tris-chloride, 0.2 M lithium sulfate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.00 Å R-free 0.143 |
| 4GJS Streptavidin-K121H Deposited 2012-08-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–183（147 aa）
Chain B
37–183（147 aa）
|
Not recorded | 0OD trichloro{(1,2,3,4,5-eta)-1,2,3,4-tetramethyl-5-[2-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)ethyl]cyclopentadienyl}rhodium(1+) × 4 RH Rhodium × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277 K；0.1 M MES, 19 % PEG500, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.85 Å R-free 0.250 |
| 4GJV Streptavidin-S112H Deposited 2012-08-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–183（147 aa）
|
Mutation：S112H | 0OD trichloro{(1,2,3,4,5-eta)-1,2,3,4-tetramethyl-5-[2-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)ethyl]cyclopentadienyl}rhodium(1+) × 4 CL CHLORIDE ION × 16 RH Rhodium × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277 K；0.1 M MES, 19 % PEG500, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.230 |
| 4IRW Co-crystallization of streptavidin-biotin complex with a lanthanide-ligand complex gives rise to a novel crystal form Deposited 2013-01-15 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
36–163（128 aa）
Fragment：UNP residues 36-163
|
Not recorded | PDC PYRIDINE-2,6-DICARBOXYLIC ACID × 48 BTN BIOTIN × 4 TB TERBIUM(III) ION × 20 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.5 uL protein (pH 8.0) incubated with saturated biotin solution + 1.5 uL 200 mM Na3[Tb(Dpa)3] + 3 uL 60% v/v MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.40 Å R-free 0.154 |
| 4JO6 Streptavidin complex with SBP-Tag Deposited 2013-03-17 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
25–183（159 aa）
Fragment：UNP residues 25-183
Chain B
25–183（159 aa）
Fragment：UNP residues 25-183
Chain C
25–183（159 aa）
Fragment：UNP residues 25-183
Chain D
25–183（159 aa）
Fragment：UNP residues 25-183
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；56% Tacsimate, 12%(w/v) glycerol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.75 Å R-free 0.242 |
| 4OKA Structural-, Kinetic- and Docking Studies of Artificial Imine Reductases Based on the Biotin-Streptavidin Technology: An Induced Lock-and-Key Hypothesis Deposited 2014-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Fragment：UNP residues 38-183
|
Mutation：S112K | 5IR [N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamidato]iridium(III) × 4 IR IRIDIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；ammonium sulfate, sodium acetate, pH 8.0, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.50 Å R-free 0.240 |
| 4Y59 Crystal structure of ALiS1-Streptavidin complex Deposited 2015-02-11 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Fragment：UNP residues 39-159
Chain B
39–159（121 aa）
Fragment：UNP residues 39-159
Chain C
39–159（121 aa）
Fragment：UNP residues 39-159
Chain D
39–159（121 aa）
Fragment：UNP residues 39-159
|
Not recorded | T21 2-[3-(trifluoromethyl)phenyl]furo[3,2-c]pyridin-4(5H)-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.1M Hepes-NaOH (pH7.0), 50%(v/v) MPD
|
Resolution 1.22 Å R-free 0.155 |
| 4Y5D CRYSTAL STRUCTURE OF ALiS2-STREPTAVIDIN COMPLEX Deposited 2015-02-11 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–160（122 aa）
Fragment：UNP residues 39-160
Chain B
39–160（122 aa）
Fragment：UNP residues 39-160
Chain C
39–160（122 aa）
Fragment：UNP residues 39-160
Chain D
39–160（122 aa）
Fragment：UNP residues 39-160
|
Not recorded | MT6 methyl 3-(4-oxo-4,5-dihydrofuro[3,2-c]pyridin-2-yl)benzoate × 3 PE3 3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL × 1 DMS DIMETHYL SULFOXIDE × 1 P6G HEXAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.1M Mes-NaOH (pH6.0), 45%(w/v) PEG1000
|
Resolution 1.20 Å R-free 0.174 |
| 4YVB Structure of D128N streptavidin Deposited 2015-03-19 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
40–159（120 aa）
Chain B
40–159（120 aa）
Chain C
40–159（120 aa）
Chain D
40–159（120 aa）
|
Mutation：D128N Mutation：D128N Mutation：D128N Mutation：D128N | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.05 M HEPES, pH 7.5 with 7.5% PEG 8000
|
Resolution 1.35 Å R-free 0.170 |
| 5B5F Crystal structure of ALiS3-Streptavidin complex Deposited 2016-05-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
40–159（120 aa）
Fragment：UNP residues 40-159
Chain B
40–159（120 aa）
Fragment：UNP residues 40-159
Chain C
40–159（120 aa）
Fragment：UNP residues 40-159
Chain D
40–159（120 aa）
Fragment：UNP residues 40-159
|
Not recorded | 6F3 N-methyl-3-(4-oxo-4,5-dihydrofuro[3,2-c]pyridin-2-yl)benzenesulfonamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MES-NaOH (pH6.0), 35%(w/v) PEG 1000, 2.0% agarose hydrogel
|
Resolution 1.20 Å R-free 0.193 |
| 5B5G Crystal structure of ALiS4-Streptavidin complex Deposited 2016-05-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
40–159（120 aa）
Fragment：UNP residues 40-159
Chain B
40–159（120 aa）
Fragment：UNP residues 40-159
Chain C
40–159（120 aa）
Fragment：UNP residues 40-159
Chain D
40–159（120 aa）
Fragment：UNP residues 40-159
|
Not recorded | SO3 SULFITE ION × 7 6FX methyl 5-(4-oxidanylidene-5~{H}-furo[3,2-c]pyridin-2-yl)pyridine-3-carboxylate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1M Tris-HCl (pH8.0), 30%(w/v) PEG 1000, 2.0% agarose hydrogel
|
Resolution 1.50 Å R-free 0.193 |
| 5CSE Streptavidin-S112Y-K121E Complexed with Palladium-Containing Biotin Ligand Deposited 2015-07-23 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–158（121 aa）
Fragment：UNP residues 37-158
Chain B
38–158（121 aa）
Fragment：UNP residues 37-158
|
Mutation：S112Y-K121E Mutation：S112Y-K121E | SVP chloro{di-tert-butyl[2-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)ethyl]-lambda~5~-phosphanyl}(1-phenylprop-1-ene-1,3-diyl-kappa~2~C~1~,C~3~)palladium × 4 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15-25% PEG 1500, 100mM SPG buffer (mixed succinic acid, sodium dihydrogen phosphate and glycine in the ratio 2:7:7; 75% at pH 4 and 25% at pH 10)
|
Resolution 1.79 Å R-free 0.256 |
| 5CSE Streptavidin-S112Y-K121E Complexed with Palladium-Containing Biotin Ligand Deposited 2015-07-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
38–158（121 aa）
Fragment：UNP residues 37-158
Chain B
38–158（121 aa）
Fragment：UNP residues 37-158
|
Mutation：S112Y-K121E Mutation：S112Y-K121E | SVP chloro{di-tert-butyl[2-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)ethyl]-lambda~5~-phosphanyl}(1-phenylprop-1-ene-1,3-diyl-kappa~2~C~1~,C~3~)palladium × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15-25% PEG 1500, 100mM SPG buffer (mixed succinic acid, sodium dihydrogen phosphate and glycine in the ratio 2:7:7; 75% at pH 4 and 25% at pH 10)
|
Resolution 1.79 Å R-free 0.256 |
| 5F2B Expanding Nature's Catalytic Repertoire -Directed Evolution of an Artificial Metalloenzyme for In Vivo Metathesis Deposited 2015-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：V47A,N49K,T114Q,A119G,K121R | 9RU [1-[4-[[5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]methyl]-2,6-dimethyl-phenyl]-3-(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-1-ium-2-yl]-bis(chloranyl)ruthenium × 4 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；1.5 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.70 Å R-free 0.206 |
| 5JD2 SFX structure of corestreptavidin-selenobiotin complex Deposited 2016-04-15 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
40–159（120 aa）
Chain B
40–159（120 aa）
Chain C
40–159（120 aa）
Chain D
40–159（120 aa）
|
Not recorded | BYY 5-[(3aS,4S,6aR)-2-oxohexahydro-1H-selenopheno[3,4-d]imidazol-4-yl]pentanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；293 K；24% PEG 1500 and 20% glycerol
|
Resolution 1.90 Å R-free 0.200 |
| 5K67 Designed Artificial Cupredoxins Deposited 2016-05-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | SI4 [CuII(biot-pr-dpea)]2+ × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；274 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4
|
Resolution 1.70 Å R-free 0.234 |
| 5K68 Designed Artificial Cupredoxins Deposited 2016-05-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | SI9 [CuII(biot-bu-dpea)]2+ × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；274 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4
|
Resolution 1.40 Å R-free 0.181 |
| 5L3Y Designed Artificial Cupredoxins Deposited 2016-05-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | CU6 [CuII(biot-et-dpea)]2+ × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；274 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4
|
Resolution 1.70 Å R-free 0.244 |
| 5N7X CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE EWVHPQFEQKAK Deposited 2017-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
Chain K
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate
0.1M Sodium cacodylate pH 6.5
15% PEG6000
|
Resolution 1.12 Å R-free 0.186 |
| 5N7X CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE EWVHPQFEQKAK Deposited 2017-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
1–183（183 aa）
Chain M
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate
0.1M Sodium cacodylate pH 6.5
15% PEG6000
|
Resolution 1.12 Å R-free 0.186 |
| 5N7X CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE EWVHPQFEQKAK Deposited 2017-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
1–183（183 aa）
Chain O
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate
0.1M Sodium cacodylate pH 6.5
15% PEG6000
|
Resolution 1.12 Å R-free 0.186 |
| 5N7X CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE EWVHPQFEQKAK Deposited 2017-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain F
1–183（183 aa）
Chain H
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate
0.1M Sodium cacodylate pH 6.5
15% PEG6000
|
Resolution 1.12 Å R-free 0.186 |
| 5N89 CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE GNSFDDWLASKG Deposited 2017-02-23 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain D
1–183（183 aa）
Chain F
1–183（183 aa）
|
Not recorded | GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Potassium chloride
0.1M HEPES pH 7.5
15% PEG6000
|
Resolution 1.27 Å R-free 0.204 |
| 5N89 CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE GNSFDDWLASKG Deposited 2017-02-23 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain H
1–183（183 aa）
Chain K
1–183（183 aa）
Chain M
1–183（183 aa）
Chain O
1–183（183 aa）
|
Not recorded | GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Potassium chloride
0.1M HEPES pH 7.5
15% PEG6000
|
Resolution 1.27 Å R-free 0.204 |
| 5N8B CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE AFPDYLAEYHGG Deposited 2017-02-23 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain D
1–183（183 aa）
Chain G
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；0.1M Magnesium chloride
0.1M Sodium citrate pH 5
15% PEG4000
|
Resolution 1.03 Å R-free 0.155 |
| 5N8E CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE RDPAPAWAHGGG Deposited 2017-02-23 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain C
1–183（183 aa）
Chain D
1–183（183 aa）
|
Not recorded | NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；0.2M Ammonium acetate
0.1M Sodium acetate pH 4
15% PEG4000
|
Resolution 1.10 Å R-free 0.153 |
| 5N8J CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE D-amino acid containing peptide GyGlanvdessG Deposited 2017-02-23 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain C
1–183（183 aa）
Chain D
1–183（183 aa）
|
Not recorded | IPA ISOPROPYL ALCOHOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1M Sodium citrate pH 5.6
20% PEG4000
20% Isopropanol
|
Resolution 1.05 Å R-free 0.193 |
| 5N8T CRYSTAL STRUCTURE OF STREPTAVIDIN D-amino acid containing peptide Gdlwqheatwkkq Deposited 2017-02-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | DLE D-LEUCINE × 1 DTR D-TRYPTOPHAN × 2 DGN D-GLUTAMINE × 1 DHI D-HISTIDINE × 1 DGL D-GLUTAMIC ACID × 1 DAL D-ALANINE × 1 DTH D-THREONINE × 1 DLY D-LYSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；0.1M Sodium citrate pH 4.5,
20% PEG4000
|
Resolution 1.61 Å R-free 0.243 |
| 5N8W CRYSTAL STRUCTURE OF STREPTAVIDIN with D-amino acid containing peptide GGwhdeatwkpG Deposited 2017-02-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium acetate
0.1M MOPS pH 7.5
12% PEG8000
|
Resolution 1.10 Å R-free 0.151 |
| 5N99 CRYSTAL STRUCTURE OF STREPTAVIDIN with cyclic peptide NQpWQ Deposited 2017-02-24 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain D
1–183（183 aa）
Chain M
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.1M Sodium citrate pH 5.5
15% PEG6000
|
Resolution 1.50 Å R-free 0.192 |
| 5N99 CRYSTAL STRUCTURE OF STREPTAVIDIN with cyclic peptide NQpWQ Deposited 2017-02-24 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain G
1–183（183 aa）
Chain I
1–183（183 aa）
Chain K
1–183（183 aa）
Chain Q
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.1M Sodium citrate pH 5.5
15% PEG6000
|
Resolution 1.50 Å R-free 0.192 |
| 5N99 CRYSTAL STRUCTURE OF STREPTAVIDIN with cyclic peptide NQpWQ Deposited 2017-02-24 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain O
1–183（183 aa）
Chain S
1–183（183 aa）
Chain U
1–183（183 aa）
Chain Y
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.1M Sodium citrate pH 5.5
15% PEG6000
|
Resolution 1.50 Å R-free 0.192 |
| 5TO2 Crystal structure of streptavidin with one wild type subunit and three mutated subunits (N23A/S27D/S45A) Deposited 2016-10-16 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–163（125 aa）
Chain B
39–163（125 aa）
Chain C
39–163（125 aa）
Chain D
39–162（124 aa）
|
Mutation：N23A, S27D, S45A Mutation：N23A, S27D, S45A Mutation：N23A, S27D, S45A | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Tris pH 8.3, 0.25 M MgCl2, 32% PEG4K
|
Resolution 1.65 Å R-free 0.234 |
| 5VCQ A Hyrdrogen Producing Hybrid Streptavidin-Diiron Catalyst Deposited 2017-03-31 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain C
1–183（183 aa）
Chain D
1–183（183 aa）
|
Not recorded | BN7 2-methylpropyl 5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；100mM TRIS pH 8.5, 200mM MgCl2, 20-30% PEG4000
|
Resolution 2.05 Å R-free 0.218 |
| 5VKX Coordination Chemistry within a Protein Host: Regulation of the Secondary Coordination Sphere Deposited 2017-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | S18 [N-(3-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide](azido)copper × 4 CU COPPER (II) ION × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL protein, 2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.37 Å R-free 0.187 |
| 5VL5 Coordination Chemistry within a Protein Host: Regulation of the Secondary Coordination Sphere Deposited 2017-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | S31 [N-(3-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}propyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide](azido)(hydroxy)copper × 4 CU COPPER (II) ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.46 Å R-free 0.260 |
| 5VL8 Coordination Chemistry within a Protein Host: Regulation of the Secondary Coordination Sphere Deposited 2017-04-25 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | S32 [N-(3-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}propyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide](hydroxy)copper × 4 CU COPPER (II) ION × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL protein, 2 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.70 Å R-free 0.215 |
| 5WBA Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - WT Deposited 2017-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Fragment：UNP residues 38-183
|
Not recorded | SI8 [N-(2-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide](hydrogen peroxido-kappaO)copper × 4 ACT ACETATE ION × 4 SO4 SULFATE ION × 4 CU COPPER (II) ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；0.1 M sodium acetate, pH 4.0, 2.6 M ammonium sulfate
|
Resolution 1.50 Å R-free 0.151 |
| 5WBB Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - S112A Deposited 2017-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Fragment：UNP residues 38-183
|
Mutation：S112A | SQ1 [N-(2-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide]copper × 4 CU COPPER (II) ION × 4 GOL GLYCEROL × 4 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；0.1 M sodium acetate, 2.6 M sodium sulfate
|
Resolution 1.50 Å R-free 0.188 |
| 5WBC Designed Artificial Cupredoxins - WT Deposited 2017-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | CU6 [CuII(biot-et-dpea)]2+ × 4 GOL GLYCEROL × 4 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；274 K；0.1 M sodium acetate, pH 4, 2.6 M ammonium sulfate
|
Resolution 1.72 Å R-free 0.168 |
| 5WBD Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - N49A Deposited 2017-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Fragment：UNP residues 38-183
|
Mutation：N49A | SI7 [N-(2-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide](hydroxy)copper × 4 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；0.1 M sodium acetate, 2.0 M sodium sulfate
|
Resolution 1.50 Å R-free 0.178 |
| 6ANX Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - WT (low exposure) Deposited 2017-08-14 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Fragment：UNP residues 38-183
|
Not recorded | SI0 [N-(2-{bis[2-(pyridin-2-yl-kappaN)ethyl]amino-kappaN}ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide](hydrogen peroxido-kappaO)hydroxycopper × 4 ACT ACETATE ION × 4 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；274 K；2.6 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.62 Å R-free 0.187 |
| 6AUC Artificial metalloproteins containing a Co4O4 active site - 2xm-Sav Deposited 2017-08-31 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, K121A | OLS N-biotin-C-Co4(mu3-O)4(Py)4(H2O)4-beta-alanine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.6 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.46 Å R-free 0.201 |
| 6AUE Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112Y-b Deposited 2017-08-31 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112Y, K121A | OL3 N-biotin-C-Co4(mu3-O)4(OAc)(Py)4(H2O)3-beta-alanine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.6 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.36 Å R-free 0.229 |
| 6AUH Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112Y-a Deposited 2017-09-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112Y, K121A | OL5 N-biotin-C-Co4(mu3-O)4(OAc)(Py)3(H2O)3-beta-alanine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.6 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.60 Å R-free 0.219 |
| 6AUL Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112Y-b Deposited 2017-09-01 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112Y, K121A | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.6 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.36 Å R-free 0.195 |
| 6AUO Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112F Deposited 2017-09-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112F, K121A | OL4 N-biotin-C-Co4(mu3-O)4(Py)3(H2O)4-beta-alanine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.6 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.70 Å R-free 0.222 |
| 6AVK Streptavidin bound to peptide-like compound KPM-6 Deposited 2017-09-02 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–159（123 aa）
Chain B
37–159（123 aa）
|
Not recorded | BZ4 N-[(2H-1,3-benzodioxol-5-yl)methyl]-2-({[(2H-1,3-benzodioxol-5-yl)methyl][2-(chloromethyl)-1,3-oxazole-4-carbonyl]amino}methyl)-N-[(4-carbamoyl-1,3-oxazol-2-yl)methyl]-1,3-oxazole-4-carboxamide × 2 HDO 1-hydroxydodecan-4-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；0.2 M potassium iodide, 20% PEG3350
|
Resolution 1.40 Å R-free 0.186 |
| 6ESS Artificial imine reductase mutant S112A-N118P-K121A-S122M Deposited 2017-10-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | 4IR {N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(chloro)[(1,2,3,4,5-eta)-1,2,3,4,5-pentamethylcyclopentadienyl]iridium(III) × 4 IR IRIDIUM ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.91 Å R-free 0.327 |
| 6ESU Artificial imine reductase mutant S112A-N118P-K121A-S122M Deposited 2017-10-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | 6IR 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[4-(2-azanylethylsulfamoyl)phenyl]pentanamide × 4 IR IRIDIUM ION × 16 ACT ACETATE ION × 4 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.78 Å R-free 0.211 |
| 6FH8 E. coli surface display of streptavidin for directed evolution of an allylic deallocase Deposited 2018-01-12 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112M-K121A | JCT biotinylated ruthenium cyclopentadienide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.64 Å R-free 0.159 |
| 6FRY Photo-Driven Hydrogen Evolution by an Artificial Hydrogenase Utilizing the Biotin-Streptavidin Technology Deposited 2018-02-16 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | 9CO [CoBr(appy)-Biot]Br × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0
|
Resolution 1.70 Å R-free 0.202 |
| 6GH7 WILDTYPE CORE-STREPTAVIDIN WITH a conjugated BIOTINYLATED PYRROLIDINE Deposited 2018-05-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Not recorded | EYW 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[(3~{R})-pyrrolidin-3-yl]pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；25 mg/mL protein in deionised water is mixed at equal volume with 51% MPD.
|
Resolution 1.08 Å R-free 0.185 |
| 6GMI Genetic Engineering of an Artificial Metalloenzyme for Transfer Hydrogenation of a Self-Immolative Substrate in E. coli's Periplasm. Deposited 2018-05-26 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
|
Mutation：S112V, E116SPLSEALTKANSPAEAYKASRGAGA, K121A | 4IR {N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(chloro)[(1,2,3,4,5-eta)-1,2,3,4,5-pentamethylcyclopentadienyl]iridium(III) × 4 IR3 IRIDIUM (III) ION × 16 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；293 K；0.1 M SPG 9 pH (Buffer)
25 %w/v PEG 1500 (Precipitant)
|
Resolution 1.60 Å R-free 0.199 |
| 6J6K Apo-state streptavidin Deposited 2019-01-15 | Different ligand/ion Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
40–158（119 aa）
Chain B
40–158（119 aa）
Chain C
40–158（119 aa）
Chain D
40–158（119 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 6LNG Rapid crystallization of streptavidin using charged peptides Deposited 2019-12-30 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–163（125 aa）
Chain B
39–163（125 aa）
Chain C
39–163（125 aa）
Chain D
39–163（125 aa）
|
Not recorded | GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；0.2 M ammonium sulfate, 0.1 M MES pH 6.5, 30% w/v polyethylene glycol
monomethyl ether 5000
|
Resolution 1.80 Å R-free 0.219 |
| 6LNG Rapid crystallization of streptavidin using charged peptides Deposited 2019-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
39–163（125 aa）
Chain F
39–163（125 aa）
|
Not recorded | GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；0.2 M ammonium sulfate, 0.1 M MES pH 6.5, 30% w/v polyethylene glycol
monomethyl ether 5000
|
Resolution 1.80 Å R-free 0.219 |
| 6M9B Wild-type streptavidin in complex with biotin solved by native SAD with data collected at 6 keV Deposited 2018-08-23 | Different construct Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Not recorded | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；13.25mg SAV WT + 0.610mg biotin in 500uL H2O
in the well: 500uL => 50% MPD
sitting drops: 1uL SAV-biot + 1uL 80% MPD, 100mM MMT pH 5.5
|
Resolution 1.55 Å R-free 0.183 |
| 6QBB Engineered streptavidin variant (ENAGY) in complex with the Strep-tag II peptide Deposited 2018-12-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；PEG MME 550, zinc sulfate, 2-(N-morpholino)ethanesulfonic acid
|
Resolution 1.52 Å R-free 0.190 |
| 6QSY Engineered streptavidin variant (H--WY) in complex with the Strep-tag II peptide Deposited 2019-02-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
|
Not recorded | PGE TRIETHYLENE GLYCOL × 12 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；293 K；polyethylene glycol 8000, lithium sulfate, tris(hydroxymethyl)aminomethane
|
Resolution 1.70 Å R-free 0.179 |
| 6QW4 Engineered streptavidin variant (ACGR) in complex with the Strep-tag II peptide Deposited 2019-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；lithium sulfate, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
|
Resolution 2.10 Å R-free 0.240 |
| 6S4Q scdSav(SASK) - Engineering Single-Chain Dimeric Streptavidin as Host for Artificial Metalloenzymes Deposited 2019-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
|
Not recorded | 4IR {N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(chloro)[(1,2,3,4,5-eta)-1,2,3,4,5-pentamethylcyclopentadienyl]iridium(III) × 4 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.85 Å R-free 0.231 |
| 6S50 scdSav(SARK)mv2 - Engineering Single-Chain Dimeric Streptavidin as Host for Artificial Metalloenzymes Deposited 2019-06-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
|
Not recorded | 4IR {N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(chloro)[(1,2,3,4,5-eta)-1,2,3,4,5-pentamethylcyclopentadienyl]iridium(III) × 4 GOL GLYCEROL × 6 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 2.00 Å R-free 0.208 |
| 6SOK Engineered streptavidin variant (VTAR) in complex with the Twin-Strep-tag peptide Deposited 2019-08-29 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
Chain C
38–163（126 aa）
Chain D
38–163（126 aa）
|
Not recorded | NH2 AMINO GROUP × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；293 K；ammonium sulfate, sodium citrate-phosphate
|
Resolution 1.96 Å R-free 0.184 |
| 6SOS Engineered streptavidin variant (ENAGY) in complex with the Twin-Strep-tag peptide Deposited 2019-08-29 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
38–163（126 aa）
Chain B
38–163（126 aa）
Chain C
38–163（126 aa）
Chain D
38–163（126 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；ammonium sulfate, sodium acetate
|
Resolution 2.20 Å R-free 0.247 |
| 6T1E Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-04 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | GOL GLYCEROL × 12 ACT ACETATE ION × 4 HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；294 K；(NH4)2SO4 1.8 M, NaCH3COO 0.1 M, pH 4.6
|
Resolution 1.30 Å R-free 0.158 |
| 6T1G Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-04 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Na-citrate 0.1 M pH 5.5, 40% PEG 600
|
Resolution 1.90 Å R-free 0.250 |
| 6T1K Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-04 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 EDO 1,2-ETHANEDIOL × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；CHES 0.1 M pH 9.5 30% PEG 3000
|
Resolution 1.20 Å R-free 0.171 |
| 6T2L Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-09 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 EDO 1,2-ETHANEDIOL × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；273 K；0.17M Na-acetate, 0.085M TRIS-HCl, pH 8.5, 25.5% PEG 4000, 15% glycerol
|
Resolution 1.00 Å R-free 0.134 |
| 6T2Y Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 6 HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M di-Sodium hydrogen phosphate 20% PEG 3350
|
Resolution 1.80 Å R-free 0.240 |
| 6T2Z Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.6M Na2HPO4 0.4M K2HPO4 0.1M Sodium citrate phosphate pH 4.2
|
Resolution 1.35 Å R-free 0.183 |
| 6T30 Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 EDO 1,2-ETHANEDIOL × 6 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M di-Sodium hydrogen phosphate 20% PEG 3350
|
Resolution 1.80 Å R-free 0.230 |
| 6T31 Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；CHES 0.1 M pH 9.5, 30% PEG 3000
|
Resolution 1.35 Å R-free 0.165 |
| 6T32 Streptavidin variants harbouring an artificial organocatalyst based cofactor Deposited 2019-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
|
Not recorded | HL9 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；CHES 0.1 M pH 9.5 30% PEG 3000
|
Resolution 1.75 Å R-free 0.191 |
| 6TIP Engineered streptavidin variant (YNAFM) in complex with the Strep-tag II peptide Deposited 2019-11-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
38–163（126 aa）
|
Not recorded | NH2 AMINO GROUP × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；ammonium sulfate, sodium acetate
|
Resolution 2.10 Å R-free 0.228 |
| 6UC3 Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions Deposited 2019-09-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | BTN BIOTIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3.5；298 K；500 ul of 0.1 M Citric Acid, pH 3.5, 3M NaCl in reservoir with 2 ul of reservoir buffer mixed with 2 ul of 10 mg/ml of protein in the drop. Crystals were soaked to pH 5.5 overnight with 3 exchanges
|
Resolution 1.84 Å R-free 0.213 |
| 6UD1 Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions Deposited 2019-09-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3.5；298 K；500 ul of 0.1 M Citric Acid, pH 3.5, 3M NaCl in the reservoir with 2 ul of reservoir buffer mixed with 2 ul of 10 mg/ml of protein in the drop. Crystals were soaked to pH 5.5 overnight with 3 exchanges
|
Resolution 1.55 Å R-free 0.192 |
| 6UD6 Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions Deposited 2019-09-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 7 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3.5；298 K；500 ul of 0.1 M citric acid, pH 3.5, 3M NaCl in the reservoir with 2 ul of reservoir buffer mixed with 2 ul of 10 mg/ml of protein in the drop. Crystals were soaked to pH 5.5 overnight with 3 exchanges
|
Resolution 1.50 Å R-free 0.190 |
| 6UD6 Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions Deposited 2019-09-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 14 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3.5；298 K；500 ul of 0.1 M citric acid, pH 3.5, 3M NaCl in the reservoir with 2 ul of reservoir buffer mixed with 2 ul of 10 mg/ml of protein in the drop. Crystals were soaked to pH 5.5 overnight with 3 exchanges
|
Resolution 1.50 Å R-free 0.190 |
| 6UDB Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions Deposited 2019-09-19 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | PEG DI(HYDROXYETHYL)ETHER × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；500 ul of 0.1 M Bis-Tris, pH 6.5, 25% w/v polyethylene glycol 3350 in the reservoir with 2 ul of reservoir buffer mixed with 2 ul of 10 mg/ml of protein in the drop
|
Resolution 1.55 Å R-free 0.201 |
| 6UDC Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions Deposited 2019-09-19 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
37–163（127 aa）
Chain B
37–163（127 aa）
Chain C
37–163（127 aa）
Chain D
37–163（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；500 ul of 0.1 M Bis-Tris, pH 6.5, 25% w/v polyethylene glycol 3350 in the reservoir with 2 ul of reservoir buffer mixed with 2 ul of 10 mg/ml of protein in the drop
|
Resolution 2.10 Å R-free 0.256 |
| 6UI0 Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases Deposited 2019-09-29 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, E101Q, S112E | QFY {N-(2-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 ACT ACETATE ION × 20 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL protein, 2.0 Ammonium Sulfate, 0.1 M sodium acetate pH 4
|
Resolution 1.40 Å R-free 0.179 |
| 6UIU Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases Deposited 2019-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, E101Q, S112E | QG7 N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL protein, 2.0 M ammonium sulfate, 0.1 M sodium acetate pH 4
|
Resolution 1.35 Å R-free 0.230 |
| 6UIY Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases Deposited 2019-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112E, K121A | QG1 {5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-N-(2-{[(pyridin-2-yl)methyl][(pyridin-2-yl-kappaN)methyl]amino-kappaN}ethyl)pentanamide}iron(2+) × 4 ACT ACETATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL protein, 2.0 M ammonium sulfate, 0.1 M sodium acetate, pH 4
|
Resolution 1.47 Å R-free 0.177 |
| 6UIZ Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases Deposited 2019-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112E, K121A | QG4 {N-(2-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(triaza-1,2-dien-2-ium-1-ide-kappaN~1~)iron(4+) × 4 ACT ACETATE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL, 2.0 M ammonium sulfate, 0.1 M sodium acetate pH 4
|
Resolution 1.85 Å R-free 0.234 |
| 6US6 Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases Deposited 2019-10-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, E101Q, S112E | QFY {N-(2-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 ACT ACETATE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL protein, 2.0 M ammonium sulfate, 0.1 M sodium acetate pH 4
|
Resolution 1.50 Å R-free 0.182 |
| 6VJK Streptavidin mutant M88 (N49C/A86C) Deposited 2020-01-16 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–160（123 aa）
Chain B
38–160（123 aa）
Chain E
38–160（123 aa）
Chain F
38–160（123 aa）
|
Mutation：N49C, A86C Mutation：N49C, A86C Mutation：N49C, A86C Mutation：N49C, A86C | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；21% PEG 3350, 8% glycerol, 100 mM Bis-Tris-Cl pH 7.5
|
Resolution 1.60 Å R-free 0.215 |
| 6VJK Streptavidin mutant M88 (N49C/A86C) Deposited 2020-01-16 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
38–160（123 aa）
Chain D
38–160（123 aa）
Chain I
38–160（123 aa）
Chain J
38–160（123 aa）
|
Mutation：N49C, A86C Mutation：N49C, A86C Mutation：N49C, A86C Mutation：N49C, A86C | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；21% PEG 3350, 8% glycerol, 100 mM Bis-Tris-Cl pH 7.5
|
Resolution 1.60 Å R-free 0.215 |
| 6VJK Streptavidin mutant M88 (N49C/A86C) Deposited 2020-01-16 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain G
38–160（123 aa）
Chain H
38–160（123 aa）
Chain K
38–160（123 aa）
Chain L
38–160（123 aa）
|
Mutation：N49C, A86C Mutation：N49C, A86C Mutation：N49C, A86C Mutation：N49C, A86C | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；21% PEG 3350, 8% glycerol, 100 mM Bis-Tris-Cl pH 7.5
|
Resolution 1.60 Å R-free 0.215 |
| 6VJL Streptavidin mutant M112 (G26C/A46C) Deposited 2020-01-16 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–183（159 aa）
|
Mutation：G26C, A46C | BTN BIOTIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；28% PEG 4000, 0.15 M ammonium sulfate, 50 mM Bis-Tris
|
Resolution 1.30 Å R-free 0.201 |
| 6VO9 Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-01-30 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.50 Å R-free 0.211 |
| 6VOB Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-01-30 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 AZI AZIDE ION × 4 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.70 Å R-free 0.197 |
| 6VOZ Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-02-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.30 Å R-free 0.206 |
| 6VP1 Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-02-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.45 Å R-free 0.197 |
| 6VP2 Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-02-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 AZI AZIDE ION × 2 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.80 Å R-free 0.199 |
| 6VP3 Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-02-01 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.65 Å R-free 0.221 |
| 6Y25 Streptavidin mutant S112R,K121E with a biotC4-1 cofactor - an artificial iron hydroxylase Deposited 2020-02-14 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–183（145 aa）
|
Mutation：S112R, K121E | O6T biotC4-1 cofactor × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.95 Å R-free 0.203 |
| 6Y2M Streptavidin mutant S112R with a biotC4-1 cofactor - an artificial iron hydroxylase Deposited 2020-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–183（145 aa）
|
Not recorded | O6T biotC4-1 cofactor × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.95 Å R-free 0.231 |
| 6Y2T Streptavidin wildtype with a biotC4-1 cofactor - an artificial iron hydroxylase Deposited 2020-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–183（145 aa）
|
Not recorded | O6T biotC4-1 cofactor × 8 GOL GLYCEROL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.55 Å R-free 0.200 |
| 6Y33 Streptavidin mutant S112R with a biotC5-1 cofactor - an artificial iron hydroxylase Deposited 2020-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–183（145 aa）
|
Not recorded | O7Q biotC5-1 cofactor × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.49 Å R-free 0.192 |
| 6Y34 Streptavidin wildtype with a biotC5-1 cofactor - an artificial iron hydroxylase Deposited 2020-02-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–183（145 aa）
|
Not recorded | O7Q biotC5-1 cofactor × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.31 Å R-free 0.198 |
| 6Y3Q Streptavidin mutant S112R_K121E with a biotC5-1 cofactor - an artificial iron hydroxylase Deposited 2020-02-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–183（145 aa）
|
Not recorded | O7Q biotC5-1 cofactor × 4 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M (NH4)2SO4, 0.1 M Na-Acetate, pH 4
|
Resolution 1.95 Å R-free 0.258 |
| 7ALX Sav-SOD: Chimeric Streptavidin-cSOD as Host for Artificial Metalloenzymes Deposited 2020-10-07 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–72（34 aa）
Chain AAA
73–183（111 aa）
Chain BBB
39–72（34 aa）
Chain BBB
73–183（111 aa）
|
Not recorded | UFW ((4S)-1,3-dimesityl-4-((5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)methyl)imidazolidin-2-yl)gold × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；20 %w/v PEG 3350 (Precipitant)
0.2 M Na K Phos (Salt)
0.1 M BIS-TRIS prop 7.5 pH (Buffer)
|
Resolution 1.80 Å R-free 0.218 |
| 7B74 Chimeric Streptavidin With A Dimerization Domain For Artificial Transfer Hydrogenation Deposited 2020-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
39–72（34 aa）
Chain AAA
73–183（111 aa）
Chain BBB
39–72（34 aa）
Chain BBB
73–183（111 aa）
Chain CCC
39–72（34 aa）
Chain CCC
73–183（111 aa）
Chain DDD
39–72（34 aa）
Chain DDD
73–183（111 aa）
|
Not recorded | 4IR {N-(4-{[2-(amino-kappaN)ethyl]sulfamoyl-kappaN}phenyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}(chloro)[(1,2,3,4,5-eta)-1,2,3,4,5-pentamethylcyclopentadienyl]iridium(III) × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20 %w/v PEG 3350 (Polymer)
0.2 M KF (Salt)
|
Resolution 1.85 Å R-free 0.218 |
| 7DY0 1.93 A cryo-EM structure of streptavidin Deposited 2021-01-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.93 Å |
| 7DY0 1.93 A cryo-EM structure of streptavidin Deposited 2021-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.93 Å |
| 7DY0 1.93 A cryo-EM structure of streptavidin Deposited 2021-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.93 Å |
| 7EFC 1.70 A cryo-EM structure of streptavidin Deposited 2021-03-21 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
|
Not recorded | BTN BIOTIN × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.70 Å |
| 7EFC 1.70 A cryo-EM structure of streptavidin Deposited 2021-03-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | BTN BIOTIN × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.70 Å |
| 7EFC 1.70 A cryo-EM structure of streptavidin Deposited 2021-03-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | BTN BIOTIN × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.70 Å |
| 7EFD 1.77 A cryo-EM structure of Streptavidin using first 40 frames (corresponding to about 40 e/A^2 total dose) Deposited 2021-03-21 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
|
Not recorded | BTN BIOTIN × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.77 Å |
| 7EFD 1.77 A cryo-EM structure of Streptavidin using first 40 frames (corresponding to about 40 e/A^2 total dose) Deposited 2021-03-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | BTN BIOTIN × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.77 Å |
| 7EFD 1.77 A cryo-EM structure of Streptavidin using first 40 frames (corresponding to about 40 e/A^2 total dose) Deposited 2021-03-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–183（183 aa）
|
Not recorded | BTN BIOTIN × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 1.77 Å |
| 7EK8 Crystal structure of apo streptavidin at ambient temperature Deposited 2021-04-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–160（123 aa）
Chain B
38–160（123 aa）
Chain C
38–160（123 aa）
Chain D
38–160（123 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；Pact PremierTM 100 mM MMT buffer pH 6.0 and 25 % w/v PEG 1500
|
Resolution 1.70 Å R-free 0.224 |
| 7EK9 Crystal structure of apo streptavidin at cryogenic temperature Deposited 2021-04-04 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–160（123 aa）
Chain B
38–160（123 aa）
Chain C
38–160（123 aa）
Chain D
38–160（123 aa）
|
Not recorded | MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 3 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 6；294 K；Pact PremierTM 100 mM MMT buffer, PEG 1500
|
Resolution 1.10 Å R-free 0.187 |
| 7KBY Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-10-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 CYN CYANIDE ION × 4 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL
2.0 M ammonium sulfate, 0.1 M sodium acetate pH 4
|
Resolution 1.70 Å R-free 0.224 |
| 7KBZ Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-10-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y Mutation：K121A, L124Y | KM3 {N-(4-{bis[(pyridin-2-yl-kappaN)methyl]amino-kappaN}butyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide}iron(3+) × 4 CYN CYANIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；295 K；26 mg/mL
2.0 M ammonium sulfate, 0.1 M sodium acetate pH 4
|
Resolution 1.90 Å R-free 0.245 |
| 7KNL Artificial Metalloproteins with Dinuclear Iron Centers Deposited 2020-11-04 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：K121A, L124Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M Ammonium Sulfate, 0.1 M Sodium Acetate pH 4
|
Resolution 1.35 Å R-free 0.241 |
| 7NLV WILDTYPE CORE-STREPTAVIDIN WITH a conjugated BIOTINYLATED PYRROLIDINE II Deposited 2021-02-22 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
37–163（127 aa）
Chain BBB
37–163（127 aa）
Chain CCC
37–163（127 aa）
Chain DDD
37–163（127 aa）
|
Not recorded | UJE 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-((S)-pyrrolidin-3-yl)pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；25 mg/mL protein in deionised water is mixed at equal volume with 52% MPD.
|
Resolution 1.29 Å R-free 0.247 |
| 7ZOF Streptavidin Iron-Porphyrin Deposited 2022-04-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Not recorded | JLL (2R)-2-[5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-[[(5Z,10Z,14Z,19Z)-15-[[[(2R)-2-[5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-sulfo-propanoyl]amino]methyl]-1,4,21,23-tetrahydroporphyrin-5-yl]methylamino]-3-oxidanylidene-propane-1-sulfonic acid × 2 IMD IMIDAZOLE × 4 FE FE (III) ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.1 M MIB 7 pH (Buffer)
22.5 %v/v PEG 1500 (Precipitant)
|
Resolution 1.74 Å R-free 0.203 |
| 7ZX9 Streptavidin with a fluorescent substrate Deposited 2022-05-20 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
|
Not recorded | K9D 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[2-[6-(3,4-dihydro-1~{H}-isoquinolin-2-yl)-1,3-bis(oxidanylidene)benzo[de]isoquinolin-2-yl]ethyl]pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate, 0.1 M sodium acetate
26 mg/ml protein
|
Resolution 1.55 Å R-free 0.199 |
| 7ZXZ dithiol-ligand bound to streptavidin Deposited 2022-05-23 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 2 K9R 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[(1~{R},3~{S})-3-[3,5-bis(sulfanylmethyl)phenyl]-2,4-bis(oxidanylidene)cyclopentyl]pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；0.1 M MIB, 25 % w/v PEG 1500
|
Resolution 1.45 Å R-free 0.204 |
| 8AQD Hydrophobic probe bound to Streptavidin - 1 Deposited 2022-08-12 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | N9O 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[2-[6-(dimethylamino)-1,3-bis(oxidanylidene)benzo[de]isoquinolin-2-yl]ethyl]pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；25 w/v% PEG 3350
0.1 M sodium acetate pH 4.0
|
Resolution 1.45 Å R-free 0.240 |
| 8AQJ Hydrophobic probe bound to Streptavidin - 2 Deposited 2022-08-12 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | N9O 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[2-[6-(dimethylamino)-1,3-bis(oxidanylidene)benzo[de]isoquinolin-2-yl]ethyl]pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；25 % w/v PEG 3350
0.1 M sodium acetate pH 4.0
|
Resolution 1.85 Å R-free 0.234 |
| 8AQO Streptavidin with a bisbiothinilated Fe4S4 cluster Deposited 2022-08-13 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Not recorded | NUI 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[2-[[20-[2-[5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethanoylamino]-2$l^{3},4,12,14$l^{3},16,24,25$l^{3},27$l^{3}-octathia-1$l^{4},3$l^{4},13$l^{4},15$l^{4}-tetraferranonacyclo[11.11.1.1^{1,13}.1^{6,10}.1^{18,22}.0^{2,15}.0^{3,14}.0^{3,25}.0^{15,27}]octacosa-6(28),7,9,18,20,22(26)-hexaen-8-yl]amino]-2-oxidanylidene-ethyl]pentanamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25 % w/v PEG 1500
0.1 M boric acid pH 8.5
(anaerobic)
|
Resolution 1.90 Å R-free 0.217 |
| 8AQX streptavidin mutant S112I with an iridium catalyst for CH activation Deposited 2022-08-14 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Not recorded | NOF tert-butyl 7'-[5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-chloranyl-2,3,4,5,6-pentamethyl-spiro[1$l^{8}-iridapentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane-1,2'-3-aza-1-azonia-2$l^{8}-iridatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12),9-pentaene]-3'-carboxylate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2 M NaCl
0.1 M BIS-TRIS 6.5 pH
25 % w/v PEG 3350
|
Resolution 1.85 Å R-free 0.211 |
| 8AQY streptavidin mutant S112A with an iridium catalyst for CH activation Deposited 2022-08-15 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Not recorded | NOF tert-butyl 7'-[5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-chloranyl-2,3,4,5,6-pentamethyl-spiro[1$l^{8}-iridapentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane-1,2'-3-aza-1-azonia-2$l^{8}-iridatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12),9-pentaene]-3'-carboxylate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M HEPES 7.5 pH
10 % w/v PEG 8K
8 % v/v EG
|
Resolution 1.65 Å R-free 0.201 |
| 8BY0 streptavidin mutant S112I K121R with an iridium catalyst for CH activation Deposited 2022-12-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Not recorded | NOF tert-butyl 7'-[5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-chloranyl-2,3,4,5,6-pentamethyl-spiro[1$l^{8}-iridapentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane-1,2'-3-aza-1-azonia-2$l^{8}-iridatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12),9-pentaene]-3'-carboxylate × 4 SO4 SULFATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2.0 M ammonium sulfate
0.1 M sodium acetate
(soaking under pH 6.0)
|
Resolution 2.10 Å R-free 0.251 |
| 8BY1 streptavidin with an iridium catalyst for CH activation Deposited 2022-12-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–158（120 aa）
|
Not recorded | NOF tert-butyl 7'-[5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-chloranyl-2,3,4,5,6-pentamethyl-spiro[1$l^{8}-iridapentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane-1,2'-3-aza-1-azonia-2$l^{8}-iridatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12),9-pentaene]-3'-carboxylate × 4 SO4 SULFATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；2 M ammonium sulfate
0.1 M sodium acetate
(soaking at pH 6.0)
|
Resolution 1.49 Å R-free 0.195 |
| 8CRN Streptavidin S112Y Co-TAML artificial metalloenzyme Deposited 2023-03-08 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
|
Not recorded | VJL Co-linked Tetra-amido macrocyclic ligand × 4 NA SODIUM ION × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M sodium acetate pH 4.0
2 M ammonium sulfate
soaking with pH change to pH 6.0
|
Resolution 2.00 Å R-free 0.208 |
| 8CRP Streptavidin WT Co-TAML artificial metalloenzyme Deposited 2023-03-08 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
|
Not recorded | VJL Co-linked Tetra-amido macrocyclic ligand × 4 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2 M ammonium sulfate,
0.1 M sodium acetate pH 4.0
for soaking pH adjustment to pH 6.0
|
Resolution 2.00 Å R-free 0.214 |
| 8GOG Structure of streptavidin mutant (S112Y-K121E) complexed with biotin-cyclopentadienyl-rhodium (III)(Cp*-Rh(III)) Deposited 2022-08-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–157（119 aa）
Chain B
39–157（119 aa）
|
Mutation：S112Y,K121E Mutation：S112Y,K121E | RH3 RHODIUM(III) ION × 8 JSU trichloro((3~{a}~{S},4~{S},6~{a}~{R})-4-[(5~{R})-5-oxidanyl-5-[2-(2,3,4,5-tetramethylcyclopenta-2,4-dien-1-ylidene)ethylamino]pentyl]-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-2-one)rhodium(3+) × 4 GOL GLYCEROL × 18 CL CHLORIDE ION × 8 SO4 SULFATE ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.7；291 K；0.2 M sodium sulfate pH 6.7 with 20% w/v PEG 3350
|
Resolution 2.00 Å R-free 0.294 |
| 8GVK Cryo-EM structure of streptavidin Deposited 2022-09-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–183（183 aa）
Chain B
1–183（183 aa）
Chain C
1–183（183 aa）
Chain D
1–183（183 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.20 Å |
| 8HRM Cryo-EM structure of streptavidin Deposited 2022-12-15 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
40–158（119 aa）
Chain B
40–158（119 aa）
Chain C
40–158（119 aa）
Chain D
40–158（119 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.56 Å |
| 8OJW Streptavidin WT artificial metalloenzyme for carboamination Deposited 2023-03-25 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–159（122 aa）
|
Not recorded | 0OD trichloro{(1,2,3,4,5-eta)-1,2,3,4-tetramethyl-5-[2-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)ethyl]cyclopentadienyl}rhodium(1+) × 4 CL CHLORIDE ION × 4 SO4 SULFATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2.0 M ammonium sulfate
0.1 M sodium acetate
-> soaking experiment by pH adjustment to pH 6.0
|
Resolution 1.48 Å R-free 0.202 |
| 8OJX Streptavidin S112YK121E artificial metalloenzyme for carboamination Deposited 2023-03-25 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–158（121 aa）
|
Not recorded | 0OD trichloro{(1,2,3,4,5-eta)-1,2,3,4-tetramethyl-5-[2-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}amino)ethyl]cyclopentadienyl}rhodium(1+) × 4 IR IRIDIUM ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；2 M ammonium sulfate
0.1 M sodium acetate pH 4.0
-> for soaking pH adjustment to pH 6.0
|
Resolution 1.60 Å R-free 0.197 |
| 8P5Y Artificial transfer hydrogenase with a Mn-12 cofactor and Streptavidin S112Y-K121M mutant Deposited 2023-05-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
|
Mutation：S112Y-K121M Mutation：S112Y-K121M Mutation：S112Y-K121M Mutation：S112Y-K121M | WZQ 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[2-(3,4-dihydro-2~{H}-pyrano[2,3-c]pyridin-6-ylmethylamino)ethyl]pentanamide × 4 MN MANGANESE (II) ION × 4 BR BROMIDE ION × 4 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Sodium/potassium phosphate, 0.1 M HEPES pH 7.5, 15 % v/v PEG, Smear High, 10 % v/v Ethylene glycol
|
Resolution 1.88 Å R-free 0.265 |
| 8P5Z Artificial transfer hydrogenase with a Mn-5 cofactor and Streptavidin S112Y-K121M mutant Deposited 2023-05-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Mutation：S112Y-K121M Mutation：S112Y-K121M Mutation：S112Y-K121M Mutation：S112Y-K121M | X08 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-[2-[(5-methylpyridin-2-yl)methylamino]ethyl]pentanamide × 4 MN MANGANESE (II) ION × 4 BR BROMIDE ION × 4 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；291 K；0.15 M Lithium sulfate, 0.05 M Magnesium chloride hexahydrate, 0.1 M Bis-Tris pH = 6.8, 25 % v/v PEG Smear Low
|
Resolution 1.56 Å R-free 0.218 |
| 8PXG Structure of Streptactin, solved at wavelength 2.75 A Deposited 2023-07-23 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–163（126 aa）
|
Not recorded | CL CHLORIDE ION × 28 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；3 M sodium chloride, 0.1 citric acid, pH 3.5
|
Resolution 1.80 Å R-free 0.194 |
| 8QEX Streptavidin variant with a cobalt catalyst for CH metal-catalyzed hydrogen-atom-transfer (M-HAT) Deposited 2023-09-01 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–71（33 aa）
Chain A
78–183（106 aa）
Chain B
39–71（33 aa）
Chain B
78–183（106 aa）
|
Not recorded | UFU cobalt Streptavidin × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.05 M Citric acid, 19 % w/v PEG 1000, 0.1 M Lithium sulfate, 0.05 M Sodium phosphate dibasic dihydrate
|
Resolution 1.90 Å R-free 0.254 |
| 8QQ3 Streptavidin with a Ni-cofactor Deposited 2023-10-03 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
|
Not recorded | WKF 4-[4-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]butylamino]-~{N}1,~{N}1'-di(quinolin-8-yl)cyclohexane-1,1-dicarboxamide × 4 NI NICKEL (II) ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M sodium acetate, 0.1 M Tris, pH 8.5, 30% w/v PEG 4K
|
Resolution 1.60 Å R-free 0.191 |
| 8TY0 Streptavidin variant S112E-K121H bound to bis-biotinylated Iron-porphyrin Deposited 2023-08-24 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Chain B
38–183（146 aa）
Chain C
38–183（146 aa）
Chain D
38–183（146 aa）
|
Not recorded | SIK Bis-biotinylated Iron-porphyrin × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；0.2 M ammonium sulfate, 0.1 M sodium acetate pH 4.5 , 20% PEG 4000
|
Resolution 1.54 Å R-free 0.191 |
| 8XG4 X-ray crystal structure of streptavidin flash-cooled in 30% glycerol at ambient pressure Deposited 2023-12-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
39–159（121 aa）
Fragment：UNP residues 39-159
Chain D
39–159（121 aa）
Fragment：UNP residues 39-159
|
Not recorded | PG6 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE × 1 GOL GLYCEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG1,000
|
Resolution 1.38 Å R-free 0.169 |
| 8XG4 X-ray crystal structure of streptavidin flash-cooled in 30% glycerol at ambient pressure Deposited 2023-12-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
39–159（121 aa）
Fragment：UNP residues 39-159
Chain C
39–159（121 aa）
Fragment：UNP residues 39-159
|
Not recorded | PG4 TETRAETHYLENE GLYCOL × 1 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG1,000
|
Resolution 1.38 Å R-free 0.169 |
| 8XG5 X-ray crystal structure of streptavidin flash-cooled in 30% PEG1000 at ambient pressure Deposited 2023-12-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
39–159（121 aa）
Fragment：Avidin-like
Chain D
39–159（121 aa）
Fragment：Avidin-like
|
Not recorded | PG4 TETRAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.40 Å R-free 0.183 |
| 8XG5 X-ray crystal structure of streptavidin flash-cooled in 30% PEG1000 at ambient pressure Deposited 2023-12-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
39–159（121 aa）
Fragment：Avidin-like
Chain C
39–159（121 aa）
Fragment：Avidin-like
|
Not recorded | PG4 TETRAETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.40 Å R-free 0.183 |
| 8XG6 X-ray crystal structure of Streptavidine without cryo-protectant using a high-pressure cryocooling method Deposited 2023-12-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
39–159（121 aa）
Fragment：Avidin-like
Chain D
39–159（121 aa）
Fragment：Avidin-like
|
Not recorded | PG6 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.31 Å R-free 0.182 |
| 8XG6 X-ray crystal structure of Streptavidine without cryo-protectant using a high-pressure cryocooling method Deposited 2023-12-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
39–159（121 aa）
Fragment：Avidin-like
Chain C
39–159（121 aa）
Fragment：Avidin-like
|
Not recorded | PG4 TETRAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.31 Å R-free 0.182 |
| 8Y23 X-ray crystal structure of ALiS4-Streptavidine complex without cryo-protectant using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | 6FX methyl 5-(4-oxidanylidene-5~{H}-furo[3,2-c]pyridin-2-yl)pyridine-3-carboxylate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.48 Å R-free 0.193 |
| 8Y24 X-ray crystal structure of ALiS4-Streptavidine complex with 10% glycerol using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 5 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.45 Å R-free 0.184 |
| 8Y25 X-ray crystal structure of ALiS4-Streptavidine complex with 20% glycerol using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | GOL GLYCEROL × 6 DMS DIMETHYL SULFOXIDE × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.45 Å R-free 0.188 |
| 8Y26 X-ray crystal structure of ALiS5-Streptavidine complex without cryo-protectant using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Fragment：UNP residues 39-159
Chain B
39–159（121 aa）
Fragment：UNP residues 39-159
Chain C
39–159（121 aa）
Fragment：UNP residues 39-159
Chain D
39–159（121 aa）
Fragment：UNP residues 39-159
|
Not recorded | DMS DIMETHYL SULFOXIDE × 4 A1LXQ dimethyl 5-(4-oxidanylidene-5~{H}-furo[3,2-c]pyridin-2-yl)benzene-1,3-dicarboxylate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.23 Å R-free 0.176 |
| 8Y27 X-ray crystal structure of ALiS5-Streptavidine complex with 10% glycerol using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Fragment：UNP residues 39-159
Chain B
39–159（121 aa）
Fragment：UNP residues 39-159
Chain C
39–159（121 aa）
Fragment：UNP residues 39-159
Chain D
39–159（121 aa）
Fragment：UNP residues 39-159
|
Not recorded | DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 3 A1LXQ dimethyl 5-(4-oxidanylidene-5~{H}-furo[3,2-c]pyridin-2-yl)benzene-1,3-dicarboxylate × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG1,000
|
Resolution 1.45 Å R-free 0.185 |
| 8Y28 X-ray crystal structure of ALiS5-Streptavidine complex with 20% glycerol using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | GOL GLYCEROL × 4 DMS DIMETHYL SULFOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.33 Å R-free 0.185 |
| 8Y29 X-ray crystal structure of ALiS2-Streptavidine complex without cryo-protectant using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | MT6 methyl 3-(4-oxo-4,5-dihydrofuro[3,2-c]pyridin-2-yl)benzoate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG1,000
|
Resolution 1.42 Å R-free 0.192 |
| 8Y2A X-ray crystal structure of ALiS2-Streptavidine complex with 10% glycerol using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | MT6 methyl 3-(4-oxo-4,5-dihydrofuro[3,2-c]pyridin-2-yl)benzoate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.34 Å R-free 0.184 |
| 8Y2B X-ray crystal structure of ALiS2-Streptavidine complex with 20% glycerol using a high-pressure cryocooling method Deposited 2024-01-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–159（121 aa）
Chain B
39–159（121 aa）
Chain C
39–159（121 aa）
Chain D
39–159（121 aa）
|
Not recorded | MT6 methyl 3-(4-oxo-4,5-dihydrofuro[3,2-c]pyridin-2-yl)benzoate × 2 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 20% PEG 1000
|
Resolution 1.50 Å R-free 0.179 |
| 8ZR1 Cocrystallization of engineered streptavidin with A9 oligo DNA Deposited 2024-06-03 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–163（125 aa）
Chain B
39–163（125 aa）
Chain C
39–163（125 aa）
Chain D
39–163（125 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 8；298 K；10 mM Tris-HCl
|
Resolution 2.60 Å R-free 0.281 |
| 8ZR2 Cocrystallization of engineered streptavidin with C9 oligo DNA Deposited 2024-06-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–163（125 aa）
Chain B
39–163（125 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 8；298 K；20 mM Tris-HCl
|
Resolution 2.50 Å R-free 0.346 |
| 8ZR2 Cocrystallization of engineered streptavidin with C9 oligo DNA Deposited 2024-06-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
39–163（125 aa）
Chain D
39–163（125 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 8；298 K；20 mM Tris-HCl
|
Resolution 2.50 Å R-free 0.346 |
| 9CST Streptavidin-E101Q-K121A bound to Cu(II)-biotin-ethyl-dipicolylamine cofactor Deposited 2024-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, K121A | QG7 N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 16 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；ammonium sulfate, sodium acetate
|
Resolution 1.13 Å R-free 0.160 |
| 9CSU Streptavidin-E101Q-S112Y-K121A bound to Cu(II)-biotin-ethyl-dipicolylamine cofactor Deposited 2024-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112Y, K121A | ACY ACETIC ACID × 4 QG7 N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；ammonium sulfate, sodium acetate
|
Resolution 1.60 Å R-free 0.207 |
| 9CSV Streptavidin-E101Q-S112Y-K121A bound to Cu(II)-biotin-ethyl-dipicolylamine cofactor, oxidized by hydrogen peroxide Deposited 2024-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112Y, K121A | QG7 N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；ammonium sulfate, sodium acetate
|
Resolution 1.60 Å R-free 0.234 |
| 9CSW Streptavidin-E101Q-S112A-K121Y bound to Cu(II)-biotin-ethyl-dipicolylamine cofactor Deposited 2024-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112A, K121Y | QG7 N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 8 ACY ACETIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；ammonium sulfate, sodium acetate
|
Resolution 1.30 Å R-free 0.189 |
| 9E6Z Streptavidin-E101Q-S112F-K121A bound to Cu(II)-biotin-ethyl-dipicolylamine cofactor Deposited 2024-10-31 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E101Q, S112F, K121A | QG7 N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 ACY ACETIC ACID × 4 CU COPPER (II) ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；296 K；ammonium sulfate, sodium acetate
|
Resolution 1.70 Å R-free 0.219 |
| 9EC5 Streptavidin-S112C-L124F bound to Cu(II)dpea cofactor, containing S-nitrosocysteine modification Deposited 2024-11-13 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：E14Q, S112C, L124F Non-standard monomer：Yes (specific site not provided by mmCIF) | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 8 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；ammonium sulfate, sodium acetate
|
Resolution 1.40 Å R-free 0.228 |
| 9EDF Streptavidin-S112C-L124F bound to Cu(II)dpea cofactor Deposited 2024-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112C, L124F | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 12 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.57 Å R-free 0.183 |
| 9EDG Streptavidin-WT bound to Cu(II)dpea cofactor Deposited 2024-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
Fragment：UNP residues 33-183
|
Not recorded | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 ACT ACETATE ION × 4 CU COPPER (II) ION × 8 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.75 Å R-free 0.197 |
| 9EDH Streptavidin-S112C-T114F bound to Cu(II)dpea cofactor Deposited 2024-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112C, T114F | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.72 Å R-free 0.222 |
| 9EDI Streptavidin-S112C-L124A bound to Cu(II)dpea cofactor Deposited 2024-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112C, L124A | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 12 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.50 Å R-free 0.202 |
| 9EDK Streptavidin-S112C-T114V bound to Cu(II)dpea cofactor Deposited 2024-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112C, T114V | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 CU COPPER (II) ION × 16 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.45 Å R-free 0.190 |
| 9EDU Streptavidin-S112C bound to Cu(II)dpea cofactor Deposited 2024-11-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–183（146 aa）
|
Mutation：S112C | A1BIA N-(3-{bis[2-(pyridin-2-yl)ethyl]amino}propyl)-5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 ACT ACETATE ION × 4 CU COPPER (II) ION × 12 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.85 Å R-free 0.183 |
| 9FFJ Artificial metalloenzyme with a nickel-based 1,10-phenanthroline cofactor and streptavidin N49M-S112V mutant Deposited 2024-05-23 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 8 A1ICD N-methyl-N-[(4,4,6,6-tetrahydroxy-4,6-dioxido-1,3,3a,5,6a-tetrahydrothien[3,4-d]imidazol-4-ium-2-yl)methyl]-5-(2,4,4-trihydroxy-2-keto-3,3a,5,6-tetrahydro-1H-thien[3,4-d]imidazol-4-ium-6-yl × 4 PEG DI(HYDROXYETHYL)ETHER × 8 SO4 SULFATE ION × 8 NH4 AMMONIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；11% w/v PEG 8000 0.1M MES 6.0 0.24M Ammonium sulfate
|
Resolution 1.27 Å R-free 0.197 |
| 9FNR Artificial metalloenzyme with a nickel-based 1,10-phenanthroline cofactor and streptavidin S112V mutant Deposited 2024-06-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
|
Not recorded | A1ICD N-methyl-N-[(4,4,6,6-tetrahydroxy-4,6-dioxido-1,3,3a,5,6a-tetrahydrothien[3,4-d]imidazol-4-ium-2-yl)methyl]-5-(2,4,4-trihydroxy-2-keto-3,3a,5,6-tetrahydro-1H-thien[3,4-d]imidazol-4-ium-6-yl × 4 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.6M Magnesium sulfate heptahydrate,0.1M HEPES 7.2, 6% v/v Glycerol
|
Resolution 1.64 Å R-free 0.206 |
| 9FOA Artificial photoenzyme with anthraquinone cofactor and wild type streptavidin Deposited 2024-06-11 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain D
39–183（145 aa）
|
Not recorded | A1ID2 ~{N}-[4-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]butyl]-9,10-bis(oxidanylidene)anthracene-2-carboxamide × 4 GOL GLYCEROL × 8 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.2M Ammonium sulfate, 20% w/v PEG 3350
|
Resolution 1.36 Å R-free 0.182 |
| 9I4R N-terminal Oic streptag II in Sav E44V-S45T-V47R-D67A-K121R variant Deposited 2025-01-26 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
Chain E
39–183（145 aa）
|
Not recorded | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.2M Ammonium citrate dibasic, 20% w/v PEG 3350
|
Resolution 1.84 Å R-free 0.213 |
| 9MFZ Streptavidin-E101Q-K121A-L124E bound to Fe(III)-biotin-pentyl-dipicolylamine cofactor Deposited 2024-12-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
38–158（121 aa）
Chain B
38–158（121 aa）
Chain C
38–158（121 aa）
Chain D
38–158（121 aa）
|
Mutation：E101Q, K121A, L124E Mutation：E101Q, K121A, L124E Mutation：E101Q, K121A, L124E Mutation：E101Q, K121A, L124E | A1BLH N-(5-{bis[(pyridin-2-yl)methyl]amino}pentyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide × 4 FE FE (III) ION × 8 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；ammonium sulfate, sodium acetate
|
Resolution 1.55 Å R-free 0.189 |
| 9PUA L-Biotin-streptavidin binding Deposited 2025-07-30 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain J
37–163（127 aa）
Chain L
37–163（127 aa）
|
Not recorded | A1CK6 5-[(3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid × 4 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；294 K；1 micro-liter protein containing 3 mM Biotin in 10 mM Tris-HCl pH 7.0 mixed with 1 micro-liter 38% Ammonium Sulfate, 100 mM Na-Acetate pH 4.5, 200 mM NaCl at 21C (294 K)
|
Resolution 0.94 Å R-free 0.147 |
| 9PUB Biotin-streptavidin binding Deposited 2025-07-30 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain J
37–163（127 aa）
Chain K
37–163（127 aa）
|
Not recorded | BTN BIOTIN × 4 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；294 K；1 micro-liter protein containing 3 mM Biotin in 10 mM Tris-HCl pH 7.0 mixed with 1 micro-liter 38% Ammonium Sulfate, 100 mM Na-Acetate pH 4.5, 200 mM NaCl at 21C (294 K)
|
Resolution 0.95 Å R-free 0.145 |
| 9QNE Streptavidin with a thiophenol cofactor as artificial hydrogen atom transferase Deposited 2025-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
|
Not recorded | A1I7Y 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(3-sulfanylphenyl)pentanamide × 4 EDO 1,2-ETHANEDIOL × 24 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.1 M MES pH 5.5, 25 % w/v PEG 4K, 0.15 M (NH4)2SO4
|
Resolution 1.84 Å R-free 0.202 |
| 9QNP Streptavidin K121W with a thiophenol cofactor as artificial hydrogen atom transferase Deposited 2025-03-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
|
Not recorded | A1I7Y 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(3-sulfanylphenyl)pentanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10 % w/v PEG 1K, 10 % w/v PEG 8K
|
Resolution 2.30 Å R-free 0.254 |
| 9QNZ Streptavidin 112Y-121W-124F with a thiophenol cofactor as artificial hydrogen atom transferase Deposited 2025-03-25 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
Chain B
39–183（145 aa）
Chain C
39–183（145 aa）
Chain D
39–183（145 aa）
|
Not recorded | A1I7Y 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(3-sulfanylphenyl)pentanamide × 4 ACT ACETATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.15 M NH4 acetate, 0.1 M BIS-TRIS pH 5.5, 45 % v/v MPD
|
Resolution 1.88 Å R-free 0.201 |
| 9QO7 Streptavidin K121M with a thiophenol cofactor as artificial hydrogen atom transferase Deposited 2025-03-25 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
39–183（145 aa）
|
Not recorded | A1I8C ~{N}-[4-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]butyl]-3-sulfanyl-benzamide × 4 EDO 1,2-ETHANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；1 M Na3 citrate, 0.1 M Na cacodylate pH 6.5
|
Resolution 2.00 Å R-free 0.278 |
312 other PDB entries and 368 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | SAV_STRAV |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–119； UniProt 40–158 Author chain B； PDBConstruct 1–119； UniProt 40–158 Author chain C； PDBConstruct 1–119； UniProt 40–158 Author chain D； PDBConstruct 1–119； UniProt 40–158 |
